Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2017

IMPACT OF CHEMOTHERAPY ON NICOTINE DEPENDENCE
Yasmin Alkhlaif

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medicine and Health Sciences Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/5175

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

IMPACT OF CHEMOTHERAPY ON NICOTINE DEPENDENCE

A thesis submitted in partial fulfillment of the requirements for the degree of M.S. Program
at Virginia Commonwealth University

By
Yasmin S. Alkhlaif
Bachelor of Pharmaceutical Sciences
Al-Arab Medical University (Benghazi University)

Director: M. Imad Damaj, PhD
Professor, Department of Pharmacology and Toxicology

Virginia Commonwealth University
Richmond, Virginia
December, 2017

ii

ACKNOWLEDGEMENTS

“Our family is a circle of love and strength. With every birth and every union, the circle grows.
Every joy shared adds more love. Every crisis faced together make the circle stronger
“(unknown). My parents raised me to be a responsible, God loving and determined person and
without their involvement, I would not overcome my weaknesses and achieve my scientific
approach. My father is my role model. He is a man of respect. I admire him as his first and
oldest daughter. He taught me how to be a hard worker, overcome all the hurdles in life and
stand powerful in hard times. I believe that nothing is impossible, because he was always
saying these words. My husband, Ahmed, has been a continuing source of support during my
journey to earn my Master. He has selflessly taken care of our newborn baby Ali while I
worked long days away from him. I thank my precious son Ali, who has strengthened my
resolve to succeed. It has been a long journey of pain and hope.

Coming to America without knowing anyone, I instantly found friends in the Damaj Lab. Julie
Meade was my first friend and teacher in the Damaj Lab. From the first experiment to how to
give compelling presentations, Julie has been there for everything. She goes out of her way to
make me feel welcome. Without her, my transition to life in America would not have been as
easy. Deniz Bagdas taught me a variety of advanced experimental techniques, scientific
writing, and professional skills that will guarantee my future career success. Deniz is not only
a postdoc; she is a compassionate friend. She inspired my life in science and encouraged me to
be sharp and determined. She is the most successful woman I have ever seen in my life. Asti
Jackson worked close with me in animal studies. Together, we did mouse handling and surgery.

iii

She was a peppy friend and I will never forget her kindness and lovely soul. I would like to
thank my other lab colleagues, Wisam Toma, Moriah Carper, Fariah Rahman, and Abigail
Park, for standing with me in my life.

I am appreciative of my mentor, Dr. M. Imad Damaj. Although I came from a different
scientific background, Dr. Damaj always believed in me as a good student. This belief made
me a strong candidate to conquer my fears and hopeless moments. He was always discussing
scientific ideas and was respectful of my opinions. I knew that I could talk with Dr. Damaj
about anything, scientific or social. As a Master’s student, he treated me equal to Ph.D.
students. He pushed me to think critically, take classes in the field of drug addiction, and to
pursue training opportunities in scientific techniques. I am grateful for all Dr. Damaj has done
for me during my Master’s degree journey. I cherish this field because of him. I pray to God
to bless him and keep our relationship after my graduation and forever.

My committee was composed of insightful, helpful, supportive members. Dr. Beardsley
brought his expertise as a behavioral pharmacologist. We had deep discussions about the
nuances of the behavioral data. Dr. Selley also shared alternate interpretations of the data, and
we speculated on putative mechanisms. Dr. Del Fabbro added his clinical expertise in cancer,
drug addiction, and the interaction. I would like to thank them for their guidance in my project.

None of this would have been possible without the help of Haji Kareem, who was instrumental
in the initial steps of applying for the Higher Committee for Education Development in Iraq
scholarship, and Dr. Dewey and Dr. Akbarali for admitting to the Pharmacology & Toxicology
Department at Virginia Commonwealth University. They have given me the opportunity that
I have always dreamed of. Overall, these two years have been unpredictable and challenging,

iv

but I would not have it any other way. I am a much stronger person and I will never forget any
moment in Dr. Damaj's lab.

v

TABLE OF CONTENTS
Acknowledgements

Page #

II

List of figures

VII

List of tables

IX

List of abbreviations

X

CHAPTER ONE
GENERAL INTRODUCTION
1.1. Prevalence and health consequences of smoking in general population

1

1.2. Prevalence of smoking in cancer population

2

1.3. Impact of smoking on cancer and health outcomes

3

1.4. Smoking behavior after diagnosis with cancer

4

1.5. Chemotherapy and its possible impact in drug dependence

8

2.

9

Nicotine and Nicotinic Acetylcholine Receptors

2.1. Nicotinic Acetylcholine Receptors

9

2.2. Mechanisms Underlying Nicotine Reward

11

2.3. Mechanisms Underlying Nicotine Withdrawal

15

2.4. Preclinical Models for Assessing Nicotine Dependence

18

3.

21

Dissertation Aims

CHAPTER TWO
Establishment of Nicotine Withdrawal Model using The Sucrose Preference Test
A- Introduction

23

B- Materials and Methods

26

C- Results

31

D- Discussion

44

vi

CHAPTER THREE
Characterization of the Impact of paclitaxel on nicotine withdrawal in mice

48

A- Introduction

48

B- Materials and Methods

50

C- Results

57

D- Discussion

67

CHAPTER FOUR
Characterization of the Impact of paclitaxel on nicotine withdrawal in mice

71

A- Introduction

71

B- Materials and Methods

73

C- Results

82

D- Discussion

92

CHAPTER FIVE
GENERAL DISCUSSION

96

A- Discussion

96

B- Future directions

99

LITERATURE CITED

100

VITA

127

vii

LIST OF FIGURES

Figure 1. Sucrose preference test during spontaneous nicotine withdrawal
in C57BL/6J mice.

34

Figure 2. Effect of chronic nicotine exposure on sucrose preference.

35

Figure 3. Nicotine withdrawal had no effect on saccharine preference.

36

Figure 4. Measurement of sucrose preference after induction of nicotine withdrawal in

nicotinic KO

mice.

38

Figure 5. Time course of time spent in the light side of nicotine-dependent mice
in the LDB test.

40

Figure 6. Time spent in the light side of LDB in nicotinic KO mice during nicotine
withdrawal.

42

Figure 7. Number of transitions of the LDB test during nicotine withdrawal.

43

Figure 8. Schematic of paclitaxel treatment regimen.

53

Figure 9. Effects of anticancer agent, paclitaxel on somatic signs of spontaneous nicotine

58

withdrawal.
Figure 10. Impact of paclitaxel on spontaneous nicotine withdrawal-induced reduction in sucrose
preference.

60

Figure 11. Influence of paclitaxel on anxiety-like behavior after induction the spontaneous nicotine
withdrawal.

62

Figure 12. The effect of paclitaxel on hyperalgesia during spontaneous nicotine
withdrawal.

64

Figure 13. Impact of paclitaxel on nicotine pharmacokinetics.

66

Figure 14. Schematic of paclitaxel treatment regimen.

77

Figure 15. Schematic of conditioned place preference apparatus and protocol.

78

Figure 16. Paclitaxel attenuated the conditioned reward effect of nicotine CPP.

83

viii
Figure 17. Morphine conditioned place preference was time-dependently diminished
by paclitaxel.

85

Figure 18. Paclitaxel did not alter highly palatable food conditioning.

87

Figure 19. Impact of paclitaxel on acute nicotine and cotinine plasma levels.

89

Figure 20. Effect of paclitaxel on acute nicotine-mediated behaviors.

91

ix

LIST OF TABLES
Table 1. Experimental design: Summary of time and duration of each behavioral test and the
mice that used in each experiment.

33

x

LIST OF ABBREVIATIONS

ANOVA
AMPA
CA2+
CDC
CeA
CPA
CPP
DA
GABA
ICSS
i.p.
KO
KOR
LDB
LDT
LHb
LC/MS/MS
MHb
MOR
MP
NA+
NAc
nAChRs
nAChRs
NMDA
PFC
s.c.
VTA
WHO
WT

analysis of variance
α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid
calcium
center for diseases and control
central nucleus of the amygdala
conditioned place aversion
conditioned place preference
dopamine
glutamate, γ- aminobutyric acid
intracranial self-stimulation
intraperitoneal
knockout
kappa opioid receptor
Light Dark Boxes
laterodorsal tegmentum
lateral habenula
liquid chromatography–mass spectrometry
medial habenula
mu opioid receptor
minipump
sodium
nucleus accumbens
nicotinic acetylcholine receptors
nicotinic acetylcholine receptors
N-methyl-D-aspartic acid
prefrontal cortex
subcutaneous
ventral tegmental area
world health organization
wild type

ABSTRACT
IMPACT OF CHEMOTHHERAPY ON NICOTINE DEPENDENCE

A thesis submitted in partial fulfillment of the requirements for the degree of M.S. Program
at Virginia Commonwealth University

By
Yasmin S. Alkhlaif
Bachelor of Pharmaceutical Sciences

Director: M. Imad Damaj, PhD
Professor, Department of Pharmacology and Toxicology

Although cigarette smoke has been implicated in a causal relationship with various types of
cancers, around 62% of all cancer patients are current smokers, recent quitters, or former
smokers. While most patients who are smokers are motivated to quit after cancer diagnosis, 25
-30% of these patients continue to smoke. Furthermore, most quitters relapse after 2-3 years
of post-chemotherapy. This represents a major health concern since several clinical studies
revealed that perpetuation of smoking in cancer populations attenuates patient's well-being and
quality of life. Smoking may impair healing, attenuate the efficacy of chemotherapy, increase
the disease complications and diminish survival rates. However, the factors that involved in
nicotine dependence in cancer patients are poorly understood. According to human research, it

was suggested that tumor site, impact of cancer therapy and disease prognosis could be
responsible of continuation of tobacco smoking among cancer patients and survivors. Recently,
chemotherapy was shown to cause emotional deficits in humans (anxiety, insomnia and
depression) and animals. In this project, we focused on the chemotherapeutic agent, paclitaxel,
because it is widely used to treat solid tumors such as lung, head, neck and breast cancer. We
previously reported that paclitaxel induced general affective deficits in mice such as anhedonia,
anxiety and depression-like behaviors. We therefore hypothesized that the chemotherapeutic
agent, paclitaxel may alter the rewarding and withdrawal properties of nicotine. We
investigated the impact of paclitaxel on spontaneous nicotine withdrawal and nicotine reward
in C57BL/6J mice by using variety of behavioral tests. Our findings showed that paclitaxel
worsened the somatic and affective signs of nicotine withdrawal in male mice as well as
attenuated of nicotine reward in the CPP assay. These behavioral changes were not due to an
impact of nicotine metabolism by paclitaxel. Overall, paclitaxel changed the behaviors during
nicotine withdrawal and reward and that suggested changing in the smoking behavior after
exposure to chemotherapy.

CHAPTER ONE
GENERAL INTRODUCTION

1. Tobacco dependence
1.1. Prevalence and health consequences of smoking in general population

Tobacco smoking is the world's leading cause of preventable premature death due to
harmful effects of inhaled tobacco smoke (Samet, 2013). Tobacco use leads to a variety of
smoking related diseases such as cardiovascular disease, chronic obstructive pulmonary
disease, diabetes and 12 types of cancers (Carter et al., 2015). Tobacco smoking causes 30%
of all cancer types. In particular, it has been reported that 90% of all lung cancers are caused
by smoking. In the United States alone approximately 50% of lung cancer patients are former
smokers (Tong et al., 1996; Dresler et al., 1995). The economic burden of smoking is very high
and it is over $300 billion dollars annually (including smoking-related health costs and
productivity losses) (CDC, 2014). Although the rate of smoking has decreased in the last
decade, the National Survey on Drug Use and Health, in 2016, reported that around 26% of
general population aged 12 or above were current tobacco smokers. Indeed, 68% of these
smokers wanted to quit smoking, 55.4% made a past-year quit attempt, 7.4% recently quit
smoking, and the relapse rate was very high (95%) (CDC, 2017; Hughes et al., 2003). Even
though the link to harmful health and economic outcomes of tobacco smoking is well-known,
the smoking is still prevalent among general population as well as patients such as cancer
populations.
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1.2. Prevalence of smoking in cancer population

In a recent survey of the American Cancer Society, Surveillance Research, 2016, the
overall 5-year survival rate for all cancer types including lung cancer increased to 59%. This
growth in survival rates of cancer patients emphasizes the importance of caring for cancer
populations. Therefore, serious work and attention are required in cancer prevention, especially
for adjustable risk factors such as smoking (Karam-Hage et al., 2016). Around 62% of all
cancer patients are current smokers, recent quitters, or former smokers (Warren et al., 2013).
Most of these three categories belong to lung or head and neck cancer (Warren et al., 2013).
Various interventional and observational studies demonstrated cessation rates of 22% to 69%
in cancer population occur directly after a cancer diagnosis especially in lung cancer patients
with good prognosis (Schnoll et al., 2003; Ostroff et al., 1995; Burke et al., 2009). Other studies
have assessed the efficacy of smoking cessation therapy with other cancer patient populations
including those with breast, prostate, cervical, or head and neck cancer and found that the shortterm (4 to 6 weeks post-intervention) cessation rates was 21-75% (Cox et al., 2002; EppingJordan et al., 1998). This high percentage of smoking abstinence continues for short term after
diagnosis and treatment with chemotherapy. The relapse rates increase in cancer populations
after 2-3 years from diagnosis and chemotherapy, suggesting that many factors could be
involved in enhancement of this relapse, one of them is chemotherapy and that will be our
focus in this research.

2

1.3. Impact of smoking on cancer and health outcomes

Tobacco smoking is detrimental to health especially for cancer patients who are under
chemoradiation treatment (Peppone et al., 2011). For instance, patients who smoke during
chemoradiation therapy for limited small cell lung cancer have lower survival rates in
comparison to non-smoker cancer patients (Videtic et al., 2003). Indeed, continuation of
smoking in cancer patients attenuates patient's well-being and quality of life. For example,
smoking induces mucositis, damages the pulmonary functions, bone necrosis and dry mouth
(Benowitz, 1988; Raber-Durlacher et al., 2011). Smoking also diminishes the efficacy of
multiple chemotherapeutic agents (Vainio et al., 2001; Browman et al., 1993) which may result
in poor prognosis. In addition, cancer patients who smoke during the chemotherapy course
have higher risks of disease complications as developing secondary cancers and death (Cox et
al., 2002). It was also found that smoking cessation and relapse prevention play a crucial role
in improving cancer survival rates and boosting the quality of life of lung cancer patients and
survivors (Cox et al., 2002; Courtney, 2015; Toll et al., 2002). Furthermore, lung cancer
patients who smoke report lower quality of life scores than smoking-free cancer patients. Many
quality of life aspects such as the physical, functional, and emotional features associated with
chemotherapy side effects (fatigue, pain, depression) and cancer symptoms can be seen in
smoking cancer patients (Gritz et al., 1998). Collectively, smoking has an impact on the
therapeutic outcome in cancer patients, which is probably contributed to the notion that tobacco
smoke-derived compounds modulate cancer progression (Yoshino and Maehara, 2007).
Indeed, tobacco smoking is a risk factor for lung carcinogenesis (Yoshino and Maehara, 2007).
More than 5,000 compounds were recognized in cigarette smoke, approximately 73
compounds (Hecht, 2012a) which are categorized as carcinogenic to both laboratory animals
and humans by the International Agency for Research on Cancer. Many studies showed
3

divergent results about nicotine in terms of carcinogenesis. These results suggested that
nicotine may be a carcinogen, tumor promoter, or co-carcinogen (Sanner and Grimsrud, 2015;
Hecht, 2012a). Consequently, tobacco smoking could be a progressive factor for many cancers
especially lung, head and neck tumors and this could worsen the prognosis and survival rates
(Hecht, 2012b; Sun et al., 2012). Therefore, smoking cessation for cancer populations is
beneficial in terms of assisting cancer patient to increase their survival rates.

1.4. Smoking behavior after diagnosis with cancer

Following cancer diagnosis, patients differ in their behavior in terms of smoking. Here,
we can divide cancer population into two types: First type, there are 25-30% who smoke prior
to diagnosis who continue to do so after diagnosis (Schnoll et al., 2003; Ostroff et al., 1995;
Gritz et al., 1991; Cox at al., 2002). Many factors involved in maintaining the smoking behavior
of these patients: they may not supply with sufficient smoking cessation aid medications and
programs. Also, they probably do not obtain social and psychological support, which is very
vital in their cases. Indeed, some studies showed that family support could enhance the
smoking cessation rates (Gritz et al., 1999). It is also possible that tobacco smoking may make
them feel better, so they keep smoking to relieve their stress, depression and anxiety. Both
cancer and chemotherapy can cause insomnia, depression and anxiety in humans (Reeves et
al., 2012). Even though it is known that nicotine has bimodal effect on anxiety (File et al.,
1998; Cheeta et al., 2001), it was shown that nicotine at particular doses attenuated the anxiety
in animal (Cohen et al., 2000) and human studies (Kassel et al., 2000). Thus, tobacco smoking
may relieve the stress, anxiety and depression which were induced by chemotherapy and/ or
cancer. Furthermore, some chemotherapy induces long-term cognitive impairment as well as
4

memory deficits in cancer populations (Reeves et al., 2012). These adverse effects may
potentiate the patients to continue smoking for sake of improving their cognition, attention and
learning. In a previous clinical study aimed at evaluating the influence of nicotine on
continuous attention, working memory, and computational processing, they demonstrated that
nicotine nasal spray enhanced the cognition and attention in male and female patients (Myers
et al., 2008). Another study reported that utilization of transdermal nicotine patches
significantly improves attentional function in people with Alzheimer's disease, schizophrenia
or ADHD and normal nonsmoking populations (Levin and Rezvani, 2002) These findings
suggest that nicotine could ameliorate the memory deficits in cancer patients. In addition, CIPN
is very serious side effects in cancer populations and may stay for up to 5 years (Skahen, 2014).
This long-term neuropathic pain may prompt cancer patients to smoke and administer nicotine
to their body. In this case, nicotine may act as an analgesic and relieve the neuropathic pain
associated with chemotherapy (Powledge, 2004; Kayte et al., 2017). A previous clinical study
was conducted in a group of women after uterine surgery, which revealed that utilization of
nicotine nasal spray as postoperative pain reliever significantly improved analgesia and
reduced morphine requirements in these patients (Flood et al., 2004). Another study involved
meta-analysis displayed that nicotine administered via tobacco smoke or other delivery systems
(eg, patch, nasal spray) generated acute analgesic effects (Ditre et al., 2016). These studies
supported the notion that nicotine may act as analgesic and in our case, it may relive CIPN.
Therefore, tobacco smoking in these patients could alleviate multiple side effects that
associated with chemotherapy. On the other hand, cancer in itself induces fatigue, depression
and general pain state (American cancer society, 2016); accompanied with side effects of
chemotherapy, this may result in changing the smoking behavior of cancer patients and
survivors. The cancer patients may believe that tobacco products are not harmful, because they
may lack the awareness about the detrimental effects of tobacco consumption. Furthermore, it
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is more possible that they are not motivated, because of their disease stage or poor prognosis
regarding their case, so they relapse or keep smoking. However, the impact of these cancer and
chemotherapy-related factors on smoking and nicotine dependence is not known. Thus, we
focused on chemotherapy as a possible factor that may involve in smoking continuation among
cancer population.
The second type of patients who showed 55-68% of cessation rates, are highly
motivated to quit smoking especially if the cancer is related to smoking such as head, neck and
lung cancers (Ostroff et al., 1995; Simmons et al., 2013). These patients also undergo cessation
aid therapy, because clinicians prefer to apply the pharmacological programs and interventions
for smoking cessation during first year of cancer diagnosis (Karam-Hage et al., 2016).
However, a year or two after the cancer diagnosis, smoking abstinence rates decrease gradually
and the recidivism rates stay high. In that regard, several studies demonstrated that smoking
rates among these cancer patients reach up to 23% (Cooley et al., 2009; Davison et al., 1982;
Karam-Hage et al., 2016), which is very similar to smoking rate in general population (26%).
This is very concerning due to the huge negative health impact and reduction in quality of life
and survival rates caused by smoking in cancer population (Fivush et al., 2015). The cause for
these high rates of relapse is not clear. A recent study found that the affective negative state
and craving during nicotine withdrawal along with cancer fatigue may play a role in this relapse
(Gritz et al., 1999). There are multiple affective symptoms that appear during nicotine
withdrawal in humans: anxiety, anhedonia, depression, restlessness and irritability. It is
possible that all these negative moods along with cancer and/or chemotherapy exacerbate the
nicotine withdrawal syndrome ending with relapse. For example, the anxiety during nicotine
withdrawal is very a prominent symptom that contributes to relapse (Zhao-Shea et al., 2016).
The enhancement of this anxiety under the cancer and/or chemotherapy may promote tobacco
relapse in cancer populations. In addition, anhedonia which is the decreased ability to
6

experience pleasure and another affective signs that also implicate in smoking relapse
(Gorwood et al., 2008), may also be intensified under cancer and/or chemotherapy.
Collectively, the negative states caused by either cancer and/or chemotherapy may
worsen nicotine withdrawal symptoms and may play a role in smoking relapse. Chemotherapy
and its adverse effects have huge impact on cancer patients in terms of physical and emotional
changes (Eckhoff et al., 2015; Bao et al., 2016; Massie, 2004; Love et al., 1982; Reeves et al.,
2012; Thornton et al., 2008). The long-term emotional changes elicited by chemotherapy (Bao
et al., 2016; Reeves et al., 2012; Gangaraju et al., 2009) along with chemotherapy-induced
peripheral neuropathy (Eckhoff et al., 2015) may fortify the negative symptoms of nicotine
withdrawal in smoking cancer abstinent. However, the impact of chemotherapy on nicotine
withdrawal was never examined. Therefore, we performed several behavioral experiments to
elucidate the influence of anticancer drugs on the negative state of nicotine withdrawal using
mouse models of nicotine dependence. A better understanding of risk factors and mechanisms
mediating these high relapse rates in cancer populations is needed to explore more efficient
interventions and therapeutic strategies to prevent smoking relapse in cancer patients and
survivors (Fivush et al., 2015).
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1.5. Chemotherapy and its possible impact in drug dependence
Paclitaxel, an antineoplastic agent, is a taxane based chemotherapeutic that act as microtubuletargeting drug. It binds to the polymerized β-tubulin comprising the microtubule polymer and
stabilizes the depolymerization of the microtubule, which leads to cell apoptosis (Pellegrini et
al., 2005). While paclitaxel is highly efficacious in the treatment of breast, ovarian, neck, and
lung cancer, it can induce severe side effects such as chemotherapy-induced peripheral
neuropathy (CIPN) symptoms, mood-related changes, and minor adverse effects as muscle
pain, joint pain, diarrhea and emesis (Eckhoff et al. 2015; Bao et al., 2016). In addition to
previous undesirable effects, paclitaxel-associated acute pain syndrome could be developed in
70% of cancer populations (Reeves et al., 2012). Patients treated with paclitaxel can show
cognitive deficits (Reeves et al., 2012), depression (Gangaraju et al., 2009), and anxiety which
can be perpetuated for up to five years or longer for some patients (Massie, 2004; Love et al.,
1982; Thornton et al., 2008). Our laboratory has been very interested in the mechanisms of
peripheral and central neurotoxicity of paclitaxel in mice. We found that paclitaxel induced
affective and sensory deficits in C57BL/6J mice. In this study, paclitaxel induced an array of
affective symptoms such as anxiety, anhedonia and depression-like behaviors as well as
allodynia as sensory deficit (Toma et al., 2017). Furthermore, we observed that paclitaxel
produced anhedonia-like signs early after its administration using sucrose preference (Toma et
al., 2017). However, by using Light Dark Boxes test, the anxiety-like signs appeared late and
continued for up to 9 weeks along with depression-like symptoms (Toma et al., 2017).
Therefore, understanding the relationship between chemotherapy, smoking behavior and
nicotine dependence is needed.
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2. Nicotine and Nicotinic Acetylcholine Receptors

2.1. Nicotinic Acetylcholine Receptors

Tobacco contains over 4000 various ingredients. However, nicotine is the
psychoactive substance, which plays a crucial role in the reward and reinforcement properties
of smoking dependence (Talhout et al., 2011; Henningfield et al., 1983). After smoke
inhalation, the smoke molecules transport the nicotine to the lungs, where it is immediately
absorbed into the pulmonary venous circulation and distributed to the central nervous system
(Benowitz et al., 2009). In the brain, nicotine mediates its reward properties and reinforcement
through binding to nicotinic cholinergic receptors (nAChRs) which classified as the Cys-loop
receptor family (Changeux et al., 1998). The nAChRs are ligand-gated ion channels, which
consist of five subunits (pentamers) that surround large water-filled pore that conduct Na+ and
Ca2+ into the neurons. The entrance of these cations into the cholinergic neurons triggers
voltage-dependent calcium channels leading to high calcium penetration (Dajas-Bailador et al.,
2004; Thornton et al., 2009; Changeux et al., 1998). One of the physiological effects of the
entry of calcium into neuron is the neurotransmitter release and signaling (Dajas-Bailador et
al., 2004). The subunits of mammalian neuronal nAChRs varied from α2-α7, α9, α10 and β2β4 (Dani et al., 2015; Dajas-Bailador et al., 2004). These receptors can present in homomeric
and heteromeric forms (Albuquerque et al., 2009). Nicotinic neuronal subunits can coexist in
distinct combinations that produce variety of effects of nAChR subtypes. Furthermore, these
receptors can present in three divergent conformational states: resting closed states, open states,
and desensitized states (Williams et al., 2011). It has been reported that high-affinity α4β2* (*
denotes the inclusion of other subunits in the receptor) nAChRs subtypes play a key role in
9

development of tobacco dependence, including its impact on central circuits involved in
reinforcement, mood reward and withdrawal effects (Picciotto et al., 2013). Particularly, during
chronic tobacco use, nicotine binds to α4β2* subtypes in the central nervous system and
upregulate this receptor (López-Hernández et al., 2004; Giniatullin et al., 2005). Chronic
nicotine exposure causes persistent functional deactivation of nAChRs as a consequence of
rapid and sustained desensitization (López-Hernández et al., 2004; Hsu et al., 1996; Dani et al.,
1996). This desensitization has been thought to promote the up-regulation of the α4β2 nAChR,
which may play a role in the withdrawal aspects of nicotine dependence (Dani et al., 1996).

2.2. Mechanisms Underlying Nicotine Reward

When nicotine stimulates nAChRs, range of neurotransmitters release in the brain. One of
them, dopamine is critical for reward and reinforcement of most drugs of abuse (Nestler, 2005).
Indeed, nicotine induces its reward effect through depolarization of dopamine cell bodies in
ventral tegmental Area (VTA) and enhance their firing rate (Picciotto et al., 1998; Zhou et al.,
2001). VTA is midbrain region and part of mesocorticolimbic dopamine pathway, which is
implicated in rewarding and motivational properties of drug of abuse (Zhou et al., 2001). This
pathway originates in the VTA and projects via the medial forebrain bundle to neural substrates
such as nucleus accumbens (NAc), medial prefrontal cortex (mPFC), amygdala, septal area,
olfactory tubercle and hippocampus (Biasi et al., 2011; Lisman et al., 2005; Wise et al., 1987).
In addition, GABAergic neurons of VTA provide the DA neurons with inhibitory input
(Kalivas et al., 2011) and there have been evidences for presence of GABA descending
projections from VTA to the tegmental pedunculopontine nucleus (TPP). TPP lies in brainstem
mesopontine region and it is crucial in DA independent reward signaling (Steininger et al.,
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1992). Furthermore, TPP and the adjacent laterodorsal tegmental nucleus (LDT) sends
excitatory glutamatergic and cholinergic projections to the VTA (Kalivas et al., 2011; Garzón
et al., 1999) as well as inhibitory GABA inputs from TPP (Charara et al., 1998). In fact, VTA
has array of nAChRs subtypes (Wooltorton et al., 2003) and nicotine can stimulate both DA
and GABAergic neurons (Mansvelder et al., 2002) which are implicated in reward effect of
drug of abuse (Phillips et al., 2003; Nader et al., 1997; Laviolette et al., 2001). Several studies
have found that α4, α6 and β2 nicotinic subunits, which are expressed on dopaminergic neurons
in the VTA, are crucial for nicotine reward and reinforcement (Maskos et al., 2005; Pons et al.,
2008; Sanjakdar et al., 2015). There have been numerous studies reporting the involvement of
mesolimbic pathway in the reward effect of nicotine. Animal studies have been performed with
blockade of dopamine receptors or 6-hydroxydopamine lesions in the mesolimbic pathway that
leads to decrease in nicotine reward-like behavior in different preclinical paradigms such as
nicotine self-administration, conditioned place preference (CPP) and intracranial selfstimulation (ICSS) (Corrigall et al., 2006; Leri et al., 2016). Furthermore, microinfusions of
the β2* selective nicotinic antagonist dihydro-ß-erythroidine (DHßE) directly into the VTA
reduces nicotine self-administration (Corrigall et al., 1994). Also, nicotine enhances dopamine
neuron firing rate and dopamine release in NAc shell, extended amygdala and PFC (Di Chiara
et al., 2000; De Biasi et al., 2011) by activation of nAChRs (Maskos et al., 2005). Further, DA
neuron of the VTA received glutamatergic, GABAergic, and cholinergic inputs that regulate
dopamine release (Dani et al., 2007). Beside DA, GABA and glutamate, there are other
neurotransmitters involved in the reward pathway such as acetylcholine, endocannabinoids,
and opioid peptides. Many studies have been shown that the N-methyl-D-aspartate (NMDA)
receptors have important role in the reinforcing effects of nicotine (Kosowski et al., 2004). For
example, infusions of glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist
LY235959 into VTA and central nucleus of the amygdala (CeA) attenuates the reinforcing
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effects of nicotine I.V. self-administration and block nicotine ICSS facilitation in rats. Another
important finding was that the competitive NMDA receptor antagonist CGP39551 significantly
decreased both nicotine-induced DA release in NAcc and the locomotor activity (Kenny et al.,
2009). In addition to NMDA receptor, α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate
(AMPA) receptors is also involved in nicotine dependence. It has been reported that systemic
administration of the competitive AMPA receptor antagonist ZK200775 (Kenny et al., 2009)
inhibited the nicotine-elicited dopamine release in NAc in an inverted U-shaped manner
(Kosowski et al., 2004). Further, exposure to acute doses of nicotine have been reported to
enhance glutamate release in the NAc (Zappettini et al., 2014).
In addition, the distribution of cholinergic and glutamatergic neurons in the laterodorsal
tegmentum (LDT) and the pedunculopontine tegmentum (PDT) induce dopamine neuron
activation in VTA that project to the NAc (Omelchenico et al., 2005; Maskos et al., 2010).
Neurotoxin lesions in cholinergic neurons of the PDT reduce nicotine self-administration in
rats (Lança et al., 2000). Acetylcholine nicotinic receptors are widely distributed pre- and postsynaptically around the mesolimbic system (Lança et al., 2000; Cragg et al., 2006; Feduccia et
al., 2012). A huge body of research has used different approaches to demonstrate the roles of
nAChRs subunits in the nicotine dependence. For example, genetically modified mice,
pharmacological antagonists, and viral re-expression methods have been utilized in various
brain regions and for nAChRs subunits. Preclinical studies such as nicotine conditioned place
preference (CPP) and nicotine I.V. self-administration that have been conducted in β2
knockout (KO) mice revealed that the nicotinic high-affinity β2-containing nAChRs have
crucial contribution in nicotine reward and reinforcement (Orejarena et al., 2012; Picciotto et
al., 1998). The co-existence of β2 subunit with the α6 and α4 subunits to form range of α6β2*,
α4β2*, α4α6β2* nAChR subtypes, which have been widely expressed in the mesolimbic
system (Champtiaux et al., 2003; Klink et al., 2001), thought to be involved in the reward
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properties of nicotine (Orejarena et al., 2012; Picciotto et al., 1998). Nicotine CPP studies
demonstrated a crucial role of the α4, α6, and β2 subunits in the NAc throughout genetically
modified mice and site specific infusions (Simmons et al., 2015). Furthermore, a genetic
mutation of the β2, α6, and α4 nAChR subunits reduced nicotine self-administration, but
nicotine self-administration was stable in WT mice (Picciotto et al., 1998; Cahir et al., 2011).
In addition, several preclinical studies suggested that the α5 subunit may serve as an inhibitory
or aversive responder that attenuates nicotine intake and rewarding effects. For instance,
enhance nicotine intake is increased in α5 KO mice in the nicotine intravenous selfadministration paradigm and do not reveal raised brain stimulated thresholds after
administration of an aversive dose of nicotine when compare to their WT counterparts (Morel
et al., 2014; Fowler et al., 2011). In line with previous observations, nicotine CPP test
maintained nicotine preference at higher doses in α5 KO but not in α5 WT mice (Jackson et
al., 2010). Similarly, β4 KO mice revealed attenuation in nicotine reinforcement and
motivation to self-administer nicotine in the nicotine intravenous self-administration test
(Harrington et al., 2015). However, β4 subunit overexpression in Tabac mice (transgenic
mouse model of the Chrnb4-Chrna3-Chrna5 gene cluster) leads to nicotine conditioned place
aversion (CPA) and a reduction in nicotine consumption (Frahm et al., 2011). The different
responses of the β4 subunit in aforementioned studies were probably due to divergent doses of
nicotine used and the various aspects of nicotine dependence explored (i.e. reward and
aversion). The most dominant nAChR subtypes in the mammalian central nervous system are
the homomeric α7 and heteromeric α4β2 (Cahir et al., 2011). It has been shown that
reexpression of β2 or α4 subunits in the VTA into null β2 or α4 mutant mice rescued nicotine
reward, suggesting that VTA α4β2*-nAChRs are crucial for nicotine reward (Cahir et al.,
2011). There have been different studies about involvement of α7 in drug reward. For instance,
α7 nAChRs has been reported to enhance dopamine release in the PFC (Livingstone et al.,
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2009) and other behavioral studies showed that α7 nAChR has minor involvement in nicotine
reward (Grottick et al., 2000; Panagis et al., 2000). Furthermore, α7 knock-in mice (mice
heterozygous for a Leu250-to-Thr substitution in the channel domain of α7 subunit, which
creates a gain-of-function mutation) had vanished nicotine preference in CPP paradigm
(Harenza et al., 2013). On the contrary, infusion of ArIB, a selective α7 nAChR antagonist, in
the NAc shell results in enhancement of nicotine intake in nicotine intravenous selfadministration paradigm (Brunzell et al., 2011). Similarly, it has been demonstrated that the
genetic mutation of α7 nAChR in mice increased nicotine conditioned place preference in the
CPP test (Harenza et al., 2013). These studies suggest that α7 nAChR may have role in
regulation of nicotine dependence.

2.3. Mechanisms Underlying Nicotine Withdrawal

Cessation from cigarette smoking causes a nicotine withdrawal syndrome that induces
a variety of severe symptoms. The nicotine withdrawal syndrome in humans has three main
features: physical, cognitive and affective signs. Physical or somatic signs include bradycardia,
gastrointestinal discomfort, and increased appetite. Smokers during withdrawal show cognitive
deficits such as difficulty concentrating, impaired memory, and affective signs such as anxiety,
depressed mood and anhedonia (Hughes, 2006; Heishman et al., 2010). Nicotine withdrawalinduced neuroadaptations is composed of many neurotransmitter systems that are also involved
in nicotine reward: glutamate, GABA, dopamine, endocannabinoid, and opioid systems
(Jackson et al., 2015).

Various nAChRs mediate nicotine withdrawal signs. In particular, the affective
component of nicotine withdrawal is mainly mediated by the β2 (Jackson et al., 2009b) α6
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(Jackson et al., 2009a) β4 and α7 (Stoker et al., 2012) as evidenced in many tests measuring
changes in affective-like disorders in rodents such as the elevated plus maze test (anxiety-like
behaviors), conditioned place aversion (CPA) and ICSS (anhedonia-like effects). The somatic
signs associated with nicotine withdrawal syndrome are mediated by α3β4* (Jackson et al.,
2014), α5 (Jackson et al., 2008; Salas et al., 2009), α2 (Salas et al., 2009), β4 (Stoker et al.,
2012; Jackson et al., 2014) and α7 nicotinic subunits (Jackson et al., 2008; Grabus et al., 2005).

Animal studies have suggested that glutamate contributes to the affective and somatic
signs elicited by nicotine withdrawal in rodents. It has also been reported that glutamate release
and NMDA stimulation play a role in the manifestation of somatic signs in nicotine withdrawn
mice (Zhao-Shea et al., 2013). During nicotine withdrawal, there is an aversive negative state.
In that regard, it has been reported that nicotine withdrawal increases brain reward thresholds
in ICSS which are thought to be depression-like behavior (Epping-Jordan et al., 1998).
Antagonism

of

α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole

Propionic

Acid

(AMPA)

glutamatergic receptor leads to an enhancement of brain reward threshold in nicotinedependent rats (Souza et al., 2013). The aforementioned evidence suggests that an attenuation
of glutamatergic transmission may be accountable for the affective signs associated with the
nicotine withdrawal.

There is also evidence that suggests the involvement of GABA neurotransmission in
the nicotine withdrawal. GABAB knockout mice showed less somatic signs in comparison to
their wildtype counterparts during nicotine withdrawal (Varani et al., 2012). Furthermore,
GABAergic neurons in the interpeduncular nucleus (IPN) are stimulated during nicotine
withdrawal and inhibiting the GABAergic neurons leads to reduction of nicotine withdrawal
somatic signs in mice (Zhao-shea et al., 2009). Nonetheless, administration of the GABAB
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receptor agonist, PAM, and antagonist elevate brain reward thresholds in ICSS that suggest
worsening of depressive-like signs (Vlachou et al., 2011). Nicotine withdrawal induces a
hypodopaminergic state illustrated by attenuated dopamine levels in the NAc of rats (Markou,
2008; Foll and Goldberg, 2009; Takahashi et al., 1995; Carboni et al., 2000), reduction in
dopamine release in the NAc (Di Chiara et al., 1988), and brain reward deficits (Epping-Jordan
et al., 1998). KOR signaling may trigger this hypofunctional dopaminergic state. KOR
neurotransmission has been implicated in mood and depressive-like behaviors (Jackson et al.,
2010). Stimulation of KOR attenuates dopamine levels in the NAc (Di Chiara et al., 1988) by
blocking dopamine release and inducing dopamine reuptake (Thompson et al., 2000).
Furthermore, KOR antagonists such as nor-BNI, JDTic, and LY2456302 reduced the physical
and affective signs of the nicotine withdrawal syndrome in rodents (Tejeda et al., 2012; Jackson
et al., 2010).
It has been shown that neural systems such as the habenulo-interpeduncular pathway
play a part in nicotine withdrawal and aversion (Salas ET AL., 2010). The habenula is
composed of two divisions: medial habenula (MHb) and the lateral habenula (LHb) (Andres et
al., 1999). The MHb is primarily implicated in nicotine dependence and it has projection to
IPN (Qin et al., 2009). nAChRs are expressed extensively in the MHb-IPN pathway (Perry et
al., 2002). Furthermore, microinjection of the nonselective nAChR antagonist mecamylamine
into the MHb or the IPN induced nicotine withdrawal symptoms in mice (Salas et al., 2009).
In addition, blockade of the β4 subunit in the IPN enhanced nicotine withdrawal somatic signs
in mice (Di Chiara et al., 1988). Finally, infusion of the α6* nAChR-selective antagonist αconotoxin MII in the MHb attenuated anxiety-like behavior in nicotine withdrawn mice (Pang
et al., 2016).
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2.4. Preclinical Models for Assessing Nicotine Dependence

There are several preclinical models used to evaluate different aspects of nicotine
dependence in rodents and nonhuman primates such as reward, reinforcement, reinstatement
and withdrawal. Drug self-administration is a model of drug reinforcement that may mimic
drug seeking and drug taking behavior in humans (Lynch et al., 2010). In this procedure, we
assume that the administration of drug of abuse reinforces the behavior that results in their
delivery (Lynch et al., 2010; Panlilio and Goldberg, 2009). Most drugs of abuse in humans
consistently demonstrated drug self-administration in rodents except for hallucinogens. Drug
self-administration models show high degree of face validity and predictive validity in
measuring drug reinforcement (Fantegrossi et al., 2008). This model is a form of operant
conditioning where the reward is the drug. Different subjects are used to undergo this operant
conditioning paradigm: humans, monkeys and rodents (Lynch et al., 2010). For example,
nicotine self-administration has been used in humans in a laboratory setting (Jones, 2013).
Most drugs of abuse reinforced behaviors such as lever presses and nose pokes for rodents and
a panel press response for monkeys (Lynch et al., 2010). When an animal presses the lever for
receiving the drug, the drug is delivered in different ways: oral, intramuscular, and most
typically via intravenous catheterization (Lynch et al., 2010; Panlilio and Goldberg, 2009).
While tobacco is most often inhaled in humans, most self-administeration studies of nicotine
are performed by intravenous catheterization which approximately has the same rapid onset of
inhaled nicotine (Levin et al., 2007; Lynch et al., 2010; Panlilio and Goldberg, 2009).
Drug discrimination is another paradigm used to study the subjective effects of drugs
of abuse. It is a procedure that categorizes different drugs of abuse according to their
interoceptive responses. In this technique, there are two principle aims: first, to determine if
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the testing drug imitates the training drug or to identify if the testing treatment may change the
response of the training drug (Solinas et al., 2006). Nicotine is one of the drugs that induced
discriminative effects in animals (Shoaib, 1998). Drug discrimination has predictive validity
for CNS-mediated compounds (McMahon, 2015). This procedure composed of a food
reinforced operant response of a lever press or nose poke in rodents. In training periods,
animals are injected with drug or vehicle and the precise lever press leads to food pellet
awarding. Drug discrimination evaluates whether testing drugs produces similar interoceptive
effects as the training treatment or whether another compound can increase the interoceptive
effects of the training treatment (Meert, 1999).
Intracranial self-stimulation (ICSS) is another model assessing abuse liability of drugs.
It is an operant conditioning procedure in which experimenter implant monopolar or bipolar
electrode in brain areas such as the medial forebrain bundle. The excitation of this bundle
results in stimulation of mesolimbic pathway (Bielajew, 1986). The electrical stimulation of
the electrode to the animal’s brain reinforces a behavior such as lever presses (Carlezon and
Chartoff, 2007). Drugs of abuse are thought to ‘facilitate’ ICSS when these drugs induce a
leftward shift of ICSS stimulation frequency-rate curves and attenuate ICSS thresholds (Negus
and Miller, 2014). Nicotine acts similar to other drugs of abuse as it facilitates ICSS stimulation
(Harris et al., 2015).
Conditioned place preference (CPP) is a Pavlovian conditioning procedure used to
evaluate drug reward (Childs and De Witt, 2009). CPP is a type of associative learning in which
different species of animals are thought to pair the rewarding effects of a drug (unconditioned
stimulus) with the context and its cues (conditioned stimulus) (Bardo and Bevins, 2000; Itzhak
et al., 2000; Huston et al., 2013). Drugs that induce pavlovian conditioning are abused in
humans (O'Brien et al., 1998; Bardo and Bevins, 2000; Itzhak et al., 2000). According to animal
models of drug relapse, the exposure to drug-related cues in dependent subjects leads to drug
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cravings (Fuchs et al., 2008). Tobacco smoking cues such as a burning cigarette or a lighter
and vapor sensitization are associated with rewarding effects induced by nicotine (Tiffany and
Stephen, 1990; Hutchison et al., 1999). These smoking cues are probably responsible for the
perpetuation of human smoking behavior (Tiffany and Stephen, 1990; Hutchison et al., 1999).
Smoking cigarettes not only results in cravings and dependence, but also causes several
symptoms such as high blood pressure and heart problems (Hutchison et al., 1999; Hughes,
2009). Drugs that cause dependence in humans can demonstrate a preference in the CPP
paradigm. The CPP test has also been successfully performed in humans (Childs and De Witt,
2009; Hiller et al., 2009). Nicotine CPP has been well-established in animal research (Walters
et al., 2006; Grabus et al., 2006; Neugebauer et al., 2011; Brunzell et al., 2015;). Nicotine has
an inverted U-shaped dose response curve in the CPP test and low doses of nicotine after
systemic administration of nicotine are commonly used in mice to elicit a significant preference
in the CPP test (Grabus et al., 2006; Sanjakdar et al., 2015).
CPP test shows some limitations that may affect the interpretation of the results:
alterations in the locomotion activity, novelty-seeking behavior on test day, and contextual
preferences for one side over the other. To examine if the treatment could alter the locomotion
behaviors of the mice, the CPP chambers are provided with infrared beams that determine the
locomotor activity of animals during the test (Granon and Changeux, 2012). Furthermore, mice
have innate behavior such as exploring novel areas or objects (Granon and Changeux, 2012).
To address this issue, the CPP boxes are 3-chamber compartments (with a central
compartment), which limits the impact of novelty-seeking behavior on test day.

Several models are used to assess nicotine withdrawal in animals. In these studies,
rodents are exposed to nicotine by different route of administrations such as oral (Grabus et al.,
2005), intravenous infusion (Muelken et al., 2015), subcutaneous (s.c.) osmotic minipump
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(Jackson et al., 2012) and chronic systemic injections (Alsharari et al., 2015). The induction of
nicotine withdrawal could be spontaneously (by removal of chronic nicotine) or precipitated
via the administration of nAChR antagonists such as the nonselective nAChR antagonist
mecamylamine. Physical symptoms of nicotine withdrawal evaluated in rodents are
hyperalgesia (Grabus et al., 2005), somatic signs, such as paw tremors, body tremors,
grooming, and backing (Damaj, 2003) and changes in locomotor activity (Gäddnäs et al.,
2000). Cognitive deficit induced by nicotine withdrawal in rodents is demonstrated by the
number of reversals, increased omissions, and reduced speed of responding in the probabilistic
reversal learning task (Ashare et al., 2015). Affective signs of nicotine withdrawal such as
anxiety-like behaviors which are investigated by the elevated plus maze test and light-dark
boxes (Jackson et al., 2015; Stoker et al., 2008), aversion state or dysphoric-related signs in the
conditioned place aversion (CPA) test (Varani et al., 2014; Jackson et al., 2010) and anhedonia
as assessed with elevated reward thresholds in ICSS (Johnson et al., 2008).
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3- Dissertation Aims

The research in this thesis focuses on the impact of anticancer agent, paclitaxel on the
nicotine rewarding properties and nicotine withdrawal symptoms in C57BL/6J mice. Based on
our previous findings in Toma et al., (2017), where we reported that paclitaxel caused
long-term sensory and affective deficits, we hypothesize that treatment with paclitaxel
will worsen nicotine withdrawal in mice. In addition, we hypothesize that the
chemotherapeutic agent, paclitaxel will cause a deficit in the rewarding properties of
nicotine. This dissertation has several specific aims in order to test the hypothesis: 1st) to
establish a spontaneous nicotine withdrawal model in C57 BL/6J mice to measure affective
signs of withdrawal such as anhedonia-like behaviors using the sucrose preference test.
Previously, several models of nicotine withdrawal were established in our lab and other labs to
evaluate the physical (somatic signs and hyperalgesia) and affective signs (anxiety). However,
in these models, there was less focus on anhedonia-like behaviors throughout the nicotine
withdrawal. Anhedonia is one of the basic emotional components of the nicotine withdrawal,
which is thought to be a predictive of smoking relapse in humans (Stoker et al., 2015; Johnson
et al., 2008; Alkhlaif et al., 2017). Furthermore, anhedonia-like signs were assessed with brain
reward thresholds, known as the current intensity that maintain operant conditioning in the
discrete-trial current-intensity intracranial self-stimulation paradigm (Stoker et al., 2015;
Johnson et al., 2008; Alkhlaif et al., 2017; Gorwood, 2008). Indeed, Anxiety along with
anhedonia symptoms could be the main drive toward attenuation of smoking cessation attempts
in humans (Stoker et al., 2015; Gorwood, 2008). Therefore, we established nicotine
withdrawal-induced anhedonia model by utilizing sucrose preference paradigm. To the best of
our knowledge, this is the first report of investigating the anhedonia-related signs by using
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sucrose preference test during nicotine deprivation. The reduction in the sucrose preference is
indicative of anhedonia-like sign, while anxiety-like behaviors are represented by attenuation
in time spent in the light side in LDB. We assessed the time-course and dose-dependency of
sucrose preference and Light Dark Boxes tests during spontaneous nicotine withdrawal in
C57BL/6J mice. In addition, we investigated the role of the β2 and α6 nicotinic subunits in
these behaviors by utilizing β2 and α6 nicotinic knockout (KO) and wild-type (WT) mice.
2nd) to investigate the impact of paclitaxel on spontaneous nicotine withdrawal using the mouse
model established is the first aim. The impact of paclitaxel on nicotine dependence is currently
unknown and this is the first research that explores its influence on nicotine withdrawal. In this
regard, we evaluated the effect of paclitaxel on both physical (somatic signs and hyperalgesia)
as well as affective signs. The somatic sign observation occurred 24 hrs after induction of
nicotine withdrawal. Hot Plate test was performed to measure the latency until the appearance
of the pain avoidance stimulus (paws licking or jumping). For affective signs: anhedonia-like
signs was assessed by using sucrose preference test, while anxiety-like signs were investigated
by LDB. Importantly, we adapted the aforementioned behavioral assays at two time points
after pretreatment with paclitaxel, early and late time points. To certain extent, these time
points mimic the cancer patients and survivors in terms of exposure to chemotherapy.
3rd) we also investigated the possible alterations of nicotine reward effect after paclitaxel
administration. We assessed the conditioned reward effect of nicotine by utilizing the
conditioned place preference test. The performance of this test was at two time points after
paclitaxel pretreatment (early and late after exposure to paclitaxel). Thus, this dissertation
seeks to elucidate the involvement of chemotherapy in altering the nicotine dependence aspects
in attempts to clarifying whether or not the chemotherapy affects smoking dependence and
intake among cancer patients and survivors.

22

CHAPTER TWO

Establishment of Nicotine Withdrawal Model using The Sucrose Preference Test

A- Introduction

Nicotine dependence is not only based on the positive reinforcing and hedonic effects
of nicotine, but it is also associated with a withdrawal syndrome that results from smoking
cessation (George et al., 2007; Kenny and Markou, 2001). Indeed, the nicotine withdrawal
syndrome in humans is represented by a variety of signs such as somatic signs that include
gastrointestinal disturbances, weight gain, decreased heart rate (American Psychiatric
Association 2000), sweating, dizziness (Hughes and Hatsukami 1986), fatigue, nausea,
constipation, and diarrhea (Shiffman, 1979). In addition to these physical signs, there are other
unpleasant negative mood symptoms that occur during smoking cessation in humans. Anxiety
and anhedonia are affective features of nicotine withdrawal that are thought to contribute to
continued tobacco use (Dawkins et al., 2007; Cook et al., 2014; American Psychiatric
Association, 2000; Hughes, 2007). It has been reported that tobacco smokers may continue
smoking to escape the loss of pleasure induced by nicotine withdrawal (Dawkins et al., 2007;
Perkins & Karelitz, 2013; Cook et al., 2014). Also, laboratory human studies suggest that
nicotine deprivation results in anhedonia (Al-Adawi and Powell, 1997; Dawkins et al., 2006;
Powell et al, 2002; Powell et al, 2004). Therefore, assessment of anhedonia induced by the
nicotine withdrawal syndrome may have clinical implications in terms of treatment of tobacco
addiction.
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Similarly, in animal studies, it has also been reported that nicotine withdrawal
following chronic nicotine administration leads to reduction of operant responding for
rewarding electrical brain stimulation using intracranial self-stimulation (ICSS) in rats and
mice, a measure of reduction in responding for positive affective stimuli (Jordan et al., 1998;
Hilario et al., 2012; Johnson et al., 2008; Stoker et al., 2015). However, the ICSS procedure is
an operant conditioning method that requires surgery, which can be labor-intensive. It also
involves a special training schedule and a distinctive apparatus (Carlezon Jr and Charltoff et
al., 2007). In this study we used two-bottle choice procedure for assessing sucrose preference
which investigate the anhedonia-like behavior in mice (Strekalova et al., 2004).

Animal models of nicotine withdrawal were developed and are useful tools for
evaluating various nicotine withdrawal behaviors. These rodent models assess several signs of
withdrawal; somatic signs, affective signs, and cognitive changes (Damaj et al., 2003; Jackson
et al., 2009b; Alkhlaif et al., 2017). For instance, precipitated, spontaneous, and conditioned
place aversion (CPA) models of nicotine withdrawal were established in our laboratory and
different laboratories (Jackson et al., 2008, 2009). These established models were used
different behavioral measures to investigate the somatic signs, hyperalgesia and anxiety-related
symptom and to a lesser extent the anhedonia-like symptoms. Here, for sake of our future
studies on paclitaxel and its effect on nicotine dependence as well as establishment of new
nicotine withdrawal model, we evaluated the nicotine withdrawal-induced anhedonia-like
signs using sucrose preference paradigm. Previously, in our lab we found that paclitaxel
produced affective deficit (anxiety, anhedonia and depression-related signs) at different time
points in C57BL/6J mice. We used sucrose preference test to measure paclitaxel-induced
anhedonia-like during and after its administration. Consequently, in our model, we focused on
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anhedonia-like symptom as one of the nicotine withdrawal aspects that could elucidate some
reasons behind the smoking relapse.

Accordingly, we establish a mouse model of spontaneous nicotine withdrawal. We
assessed the time-course and dose-dependency of sucrose preference during nicotine
withdrawal in C57BL/6J mice. In addition, we investigated the role of the β2 and α6 nicotinic
subunits in this behavior by utilizing β2 and α6 nicotinic knockout (KO) and wild-type (WT)
mice. It has been previously reported that the affective signs of nicotine withdrawal including
reduction in responding for positive affective stimuli were absent in these KO mice (Jackson
et al. 2008; 2009b; Stoker et al., 2008). Finally, we compared the results of the sucrose
preference test to another well-established affective sign of nicotine withdrawal, the reduction
in time spent in light side by using the Light Dark Box (LDB) test.
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B. Materials and Methods
Animals
8-week-old male C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor,
ME). C57BL/6J provided the background strain for our α6 and β2 KO and WT mice. The β2
KO mice (Institut Pasteur, Paris, France) and their WT littermates were bred in an animal care
facility at Virginia Commonwealth University. Healthy, viable mice null for the α6 nicotinic
subunit were provided by Dr. Uwe Maskos at Institut Pasteur (Paris, France) (Champtiaux et
al., 2002). All mice used in each experiment were backcrossed at least 10 to 12 generations.
Mutant and wild types were obtained from crossing heterozygote mice. This breeding scheme
controlled for any irregularities that might occur with crossing solely mutant animals. Animals
were 8-10 weeks of age at the beginning of the experiments and were group-housed (four
animals per group with ad libitum access to food and water under a 12 hr light/dark cycle in a
21 °C). Experiments were approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University and followed the National Institutes of Health Guidelines
for the Care and Use of laboratory animals.

Drugs
(-)-Nicotine hydrogen tartrate [(-)-1-methyl-2-(3- pyridyl) pyrrolidine (þ)-bitartrate], sucrose
and saccharine were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Nicotine was
dissolved in sterile physiological saline (0.9% sodium chloride). Nicotine (12 and 24
mg/kg/day) was infused through 14-day subcutaneous osmotic minipumps (model 2002, Alzet,
Palo Alto, CA, USA). The doses were expressed as the free base of the drug. The doses were
used according to the previous literature (Damaj et al., 2003; Salas et al., 2004). Sucrose (2%)
and saccharine (0.4%) were dissolved in water and given orally in the two-bottle choice
procedure.
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Induction of Nicotine Withdrawal
Mice were anesthetized by inhaling isoflurane/oxygen vapor mixture (1–3%). Alzet osmotic
minipumps were then implanted subcutaneously within the mice for 14 days. The Alzet
minipumps were filled with either nicotine or saline solutions and inserted by making an
incision parallel to the spine at shoulder level of the mice. The wound was closed using wound
clips and the mice were placed in a surgery room for recovery before using them in
experiments. Post-operative care was done for 14 days by observing the mice daily. For all of
the procedures, the doses of nicotine were 12 and 24 mg/kg/day, calculated according to body
weight. On day 15 spontaneous nicotine withdrawal was induced by removing the minipumps
under isoflurane anesthesia in aseptic surgical conditions. The experiment was adapted as
previously described (Damaj et al., 2003; Jackson et al., 2008). On day 16, mice were tested
for sucrose preference, saccharin preference and LDB for several days. Summary of time and
duration of each behavioral test and the mice that used in each experiment was shown in Table
1.

Sucrose Preference Test
Sucrose preference test was used to investigate the reduction in responding for positive
affective stimuli in rodents (Strekalova et al., 2004) after the induction of nicotine withdrawal.
In this experiment, mice were individually housed and acclimated to cages with food and water.
Mice had free access to two 30 ml sipper tubes containing tap water for 3 days as a baseline.
Animals then were exposed to two 30 ml sipper tubes, one with tap water and the other with
2% sucrose solution. Measurements of consumed water and sucrose solution were taken every
24 hrs. To prevent any bias, tube placement was switched daily. 24 hrs following saline and
nicotine minipump removal, the same cohort of C57BL/6J mice were tested for sucrose
preference for 9 consecutive days. For the experiments using KO mice, the measurements of
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sucrose preference were taken at day 2 after removal of osmotic minipumps. Sucrose
preference was determined as the percentage of 2% sucrose volume consumed over the total
fluid intake volume. Sucrose preference (percentage) was calculated as follows: preference =
[sucrose solution intake (ml)/total fluid intake (ml)] × 100. The experiment was adapted as
previously described (Toma et al., 2017; Pothion et al., 2004). Same cohorts of C57BL/6J male
mice (n =11 per group) were tested for 11 consecutive days during chronic nicotine exposure
and 9 consecutive days after nicotine minipumps removal. For KO mice, we tested (n=8 per
group) at day 2 (48hrs) after removal of minipumps.

Saccharine Preference Test
Male C57BL/6J mice were individually housed and acclimated to cages with free access to
food and water for 3 days. Same cohort of mice were tested for 24 hrs with access to two
30 ml sipper tubes. One tube was filled with tap water and the other with 0.4% saccharin
solution. The measurements were taken at 24, 48 and 96 hrs after removal of nicotine or
saline minipumps. Saccharin preference (percentage) was calculated as follows: preference =
[saccharine solution intake (ml)/total fluid intake (ml)] × 100. The experiment was conducted
as previously described (Jastrzębska et al., 2016). We used same cohorts of C57BL/6J male
mice (n=8) for 3 days after removal of minipumps.

Light-Dark Box (LDB) Test
The LDB procedure depends on the innate aversive behavior of rodents to bright areas as well
as their stress induced-natural exploratory response (Crawley and Goodwin, 1980). The test
was slightly modified as previously reported (Wilkerson et al., 2016). The LDB apparatus is
composed of a small, enclosed dark or black compartment (36 x 10 x 34 cm) with a passageway
(6 x 6 cm) extending to a larger, light or white compartment (36 X 21 X 34 cm). The mice
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were habituated to the experiment room for 30 minutes before testing. First, mice were placed
in the light chamber and allowed to freely explore the apparatus for 5 min. Then the number of
entries into the light compartment, the number of transitions and the total time spent in the light
compartment were recorded for 5 min by a video monitoring technique and ANY-MAZE
software (Stoelting Co., Wood Dale, IL). Same cohorts of C57BL/6J male mice (n =10 per
group) were tested at days 1, 2 and 5 after nicotine minipumps removal. For KO mice, we
tested same cohort of male mice (n=8 per group) at day 2 (48hrs) after removal of minipumps.
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Statistical Analysis
The data were analyzed with GraphPad Prism software, version 6 (GraphPad Software, Inc.,
La Jolla, CA), and expressed as mean ± SEM. Studies using mutant mice were analyzed with
an ordinary two-way analysis of variance (ANOVA) test with genotype (KO versus WT) and
treatment (saline versus nicotine) as between-subject factors in conjunction with a Tukey posthoc test. Experiments using C57BL/6J mice were analyzed with two-way repeated measure
(RM) ANOVA with treatment (nicotine versus saline) and multiple time points as a between
subject design followed by the Sidak post hoc test. Prior to the ANOVA test, results were first
assessed for the normality of the residuals and homogeneity of variance. Variances were
similar between groups and were assessed using either the F‐test or Levene's test. All data
passed these tests. Differences were considered to be significant at p < 0.05.
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C. Results
Decrease in responding for positive affective stimuli in sucrose preference test during
nicotine withdrawal
To assess the attenuation in responding for positive affective stimuli as a measurable sign for
nicotine withdrawal, we assessed sucrose preference in nicotine withdrawn C57BL/6J mice for
9 days after nicotine minipump removal (Table 1). A reduction in sucrose preference is thought
to be an indication of reduction in positive affective stimuli (Strekalova et al., 2004). In Fig. 1,
a two-way RM ANOVA revealed a significant reduction of sucrose preference in nicotineinfused groups in a dose and time dependent manner [Ftreatment (2, 20) = 71.17, p<0.001, Ftime
(8, 80) = 24.61 and Finteraction (16,160) = 10.8, p<0.001; n=11]. At days 1, 2 and 3, mice treated
with 12 mg/kg/day of nicotine demonstrated significant attenuation in sucrose preference when
compared to the saline group (p<0.001). Similarly, at days 1, 2, 3 and 4, the group infused with
24 mg/kg/day of nicotine had significantly less sucrose preference in comparison to the saline
group (p<0.001). Furthermore, at days 1, 2, and 4 after removal of minipumps, mice implanted
with 24 mg/kg/day nicotine minipumps showed significant decreases in sucrose preference
when compared to the group that received 12 mg/kg/day of nicotine (p<0.001). In addition,
two way RM ANOVA revealed no significance difference in sucrose preference between
chronically exposed nicotine (24 mg/kg/day) and saline treated mice [Ftreatment (1,10)= 1.343,
p= 0.2734, Ftime (10,100)= 1.355, p= 0.2123 and Finteraction (10,100)= 0.8335, p= 0.5975; n=11;
Fig. 2]. Furthermore, in order to rule out a change in sweet taste after nicotine withdrawal, we
conducted in a separate cohort of mice, the saccharine preference test (0.4%) in C57BL/6J male
mice on days 1, 2 and 4 after removal of nicotine (24 mg/kg/day for 14 days) and saline
minipumps. As shown in Fig. 3, no reduction of saccharine preference was observed after
nicotine withdrawal. There were no significant differences between nicotine and control groups
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on saccharine preference [Ftreatment (1, 7) =1.188, p= 0.3117; Ftime (2, 14) = 8.719, p= 0.0035;
Finteraction (2, 14) = 0.905, p= 0.4268; n=8].

32

Table 1. Experimental design: Summary of time and duration of each behavioral test and the
mice that used in each experiment.

Assay

Mice Genotypes

Sucrose Preference Test

C57BL/6J, n=11
KO (β2 or α6), n=8
Light Dark Boxes Test
C57BL/6J, n=10
KO (β2 or α6), n=8
Saccharine
Preference C57BL/6J, n=8
Test
ND, not determined; Hr, hour.
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Testing after removal of
MP
For 9 consecutive days
At 48 hr
At 24,48 and 120 hr
At 48 hr
At 24,48 and 96 hr

Figure 1. Sucrose preference test during spontaneous nicotine withdrawal in C57BL/6J
mice.

C57BL/6J male mice were exposed to two sipper tubes, one containing normal drinking water
and the other containing a 2% sucrose solution, for 24 hrs per day. Sucrose preference was
determined as the percentage of 2% sucrose volume consumed over the total fluid intake
volume. Mice were chronically exposed to nicotine (12 and 24 mg/kg/day) via osmotic
minipumps then the sucrose preference was measured for 9 consecutive days after removal of
minipumps. Sucrose preference deficit was observed in nicotine withdrawn groups when
compared to saline group. Also, there was a dose dependent effect in nicotine treated groups at
days 1, 2 and 4 during nicotine withdrawal. Each point represents the mean ± S.E.M. of 11
mice per group. *Denotes P < 0.05 from saline group; # Denotes P < 0.05 from nicotine 12
mg/kg/day treated-group.
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Figure 2. Effect of chronic nicotine exposure on sucrose preference.
Mice were chronically exposed to saline or nicotine (24mg/kg/day) by osmotic subcutaneous
minipumps for 14 days. Sucrose preference test (2%) was conducted 24 hrs after implantation
of minipumps and continued for 11 consecutive days. There was no significant difference of
sucrose preference between nicotine and saline treated groups. Each point represents the mean
± S.E.M. of 11 mice per group.
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Figure 3. Nicotine withdrawal had no effect on saccharine preference.
Two days after removal of minipumps, mice undergoing nicotine withdrawal were exposed to
two tubes: one containing drinking water and the other 0.4% of saccharine. After 24, 48 and
96 hrs, measurements of water and saccharine were recorded. Saccharine preference was
determined as the percentage of 0.4% saccharine volume consumed over the total fluid intake
volume. There was no alteration in saccharine preference in nicotine withdrawn mice compared
to their controls. Each point represents the mean ± S.E.M. of 8 mice per group.
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Sucrose preference during nicotine withdrawal in β2 KO and α6 KO mice

We used the spontaneous nicotine withdrawal model to test the role of β2 and α6 nicotinic
subunits in nicotine withdrawal-induced decrease in sucrose preference by using β2 and α6
mutant mice. Based on the time course in Fig. 1, we measured sucrose preference in WT and
KO mice at 48 hrs after minipump removal (see Table 1). Interestingly, nicotine
(24mg/kg/day) treated β2 WT mice showed significantly lower sucrose preference than their
saline counterparts [Ftreatment (1, 28) = 18.69; p= 0.0002; n=8], but the effect of nicotine was
abolished in β2 KO mice. Indeed, there was a significant effect of genotype when we compared
nicotine treated β2 WT and KO groups [Fgenotype (1, 28) = 10.27; p=0.0034]. In addition, the
interaction between nicotine treatment and genotype was significant between the same subjects
[Finteraction (1, 28) = 12.58; p= 0.0014; n=8; Fig. 4A]. Similarly, nicotine infused α6 WT mice
demonstrated an attenuation of sucrose preference when compared to their controls [Ftreatment
(1, 28) = 14.14; p= 0.008)]. This effect was absent in α6 KO mice [Fgenotype (1, 28) = 9.516, p=
0.0045]. Two-way ANOVA revealed a significant effect of interaction between genotype and
treatment [Finteraction (1, 28) = 24.19; p< 0.0001; n=8; Fig. 4B].
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Figure 4. Measurement of sucrose preference after induction of nicotine withdrawal in
nicotinic KO mice.
β2 and α6 KO and WT mice were chronically infused with nicotine (24 mg/kg/day) for 14
days. Minipumps were removed from mice on day 15, and sucrose preference (2%) was
performed 48 hrs later. A) Sucrose preference test of β2 WT and KO mice at day 2 after
removal of minipumps. B) Sucrose preference results of α6 WT and KO mice. Each point
represents the mean ± S.E.M. of 8 mice per group. * Denotes p < 0.05 vs. Saline groups, #
Denotes p < 0.05 vs. nicotine withdrawn WT mice.
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Decrease in time spent in the light side in LDB during nicotine withdrawal

We measured the time spent in the light chamber of nicotine-dependent C57BL/6J mice in the
LDB assay. Using the same cohorts of mice that underwent the spontaneous nicotine
withdrawal in the sucrose preference test. It has been show that the reduction in time spent in
the light side of LDB occur during nicotine withdrawal (Jonkman et al., 2005). There was a
significant difference between nicotine withdrawn mice and saline treated mice observed by
changes in time spent in the light compartment [2-way RM ANOVA, [Ftreatment (2, 18) = 12.26,
p= 0.0004], [Ftime (2, 18) = 10.93, p= 0.0008] and [Finteraction (4, 36) = 2.114, p= 0.0993; n=10;
Fig. 5] (see Table 1). As seen in Fig. 5, mice undergoing spontaneous nicotine withdrawal
spent less time in the light compartment of the LDB apparatus compared to saline controls (p=
0.0004). This experiment continued for 5 days after induction of spontaneous nicotine
withdrawal. On day 2 after removal of minipumps, mice that were infused with 12 mg/kg/day
of nicotine significantly spent less time in the light side when compared to saline group (p=
0.0004). In addition, at day 1 and 2, the 24 mg/kg/day nicotine exposed group had a significant
reduction in the time spent in the light side when compared to their saline counterparts (p=
0.0004). Furthermore, at day 2 there was a significant difference between the two nicotine
groups (p= 0.0004). Simultaneously, transition numbers were recorded and serve as an index
of activity and exploration. In that regard, no significant difference was found in number of
transitions between nicotine and saline treated C57BL/6J male mice [2-way RM ANOVA,
Ftreatment (2, 18) =0.162, p= 0.8515, [Ftime (2, 18) = 0.146, p= 0.8645] and [Finteraction (4, 36) =
0.918, p= 0.4637; n=10]; (Fig. 7A).
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Figure 5. Time course of time spent in the light side of nicotine-dependent mice in the
LDB test.
Mice were chronically infused with saline or nicotine (12 or 24 mg/kg/day) for 14 days. On
day 15 mice underwent spontaneous nicotine withdrawal and the LDB test was performed at
days 1, 2 and 5 after removal of minipumps. Each point represents the mean ± S.E.M. of 10
mice per group. *Denotes P < 0.05 from vehicle control, # Denotes from 12 mg/kg/day nicotine
withdrawn group.
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Attenuation of time spent in the light side in the LDB test in β2 KO and α6 KO mice
undergoing nicotine withdrawal

We utilized same β2 and α6 mutant mice cohorts to evaluate the nicotine withdrawal effect on
time spent in the light side of the LDB test. Based on the time course in Fig. 5, we measured
the time recorded in the light side in the LDB in WT and KO mice 48 hrs after minipump
removal. Nicotine (24 mg/kg/day) infused β2 WT mice significantly spent lower time in the
light side when compared to their saline controls [2-way ANOVA, [Ftreatment (1, 28) = 4.255,
p= 0.0485], [Fgenotype (1, 28) = 2.667, p= 0.013] and [Finteraction (1, 28) = 5.91, p= 0.0217; n=8;
Fig. 6A]. However, nicotine withdrawal-induced reduction in time spent in light side was not
present in β2 KO mice (p>0.05). Furthermore, nicotine treated β2 WT exhibited lower time
spent in the light chamber in comparison to the nicotine β2 KO group (p= 0.013). Similarly, as
seen in Fig. 6B, chronic nicotine exposed α6 WT mice demonstrated lower time spent in light
side of the apparatus in comparison to the saline treated α6 WT mice [Ftreatment (1,28) = 12.77;
p= 0.0013]. However, nicotine dependent α6 KO mice did not show a significant difference
when compared to saline treated α6 KO mice (p>0.05). In addition, two-way ANOVA revealed
a significant effect of genotype [Fgenotype (1, 28) = 7.212; p= 0.012] and [Finteraction (1, 28) =
10.4; p= 0.032; n=8; Fig. 6B] (see Table 1). Nicotine withdrawn α6 WT mice spent lower time
in the light compartment when compared to nicotine treated α6 KO mice (p= 0.012).
Furthermore, two-way ANOVA did not demonstrate significant difference in number of
transitions between saline and nicotine groups in genetically modified β2 [Ftreatment
(1,28)=0.002, p= 0.9639], [Fgenotype (1,28)= 0.752, p= 0.3931] and [Finteraction (1,28)= 0.168, p=
0.6843; n=8] (Fig. 7B) and α6 mice [Ftreatment (1,28)= 0.633,p= 0.4328],[Fgenotype (1,28)=
0.085,p= 0.7715] and [Finteraction(1,28)= 0.2123, p= 0.6485; n=8] (Fig. 7C).
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Figure 6. Time spent in the light side of LDB in nicotinic KO mice during nicotine
withdrawal.
β2 and α6 KO/WT mice were chronically infused with nicotine (24 mg/kg/day) for 14 days.
Minipumps were removed from mice on day 15, and the LDB test was performed 48 h later.
A) Nicotine withdrawn β2 WT mice exhibited an attenuation of time spent in the light side on
day 2 after removal of minipumps. But this effect was not seen in β2 KO mice. B) Similarly,
α6 WT mice displayed a reduction in the time spent in the light side on day 2 that was not
observed in α6 KO mice. Each point represents the mean ± S.E.M. of 8 mice per group. *
Denotes p < 0.05 vs. Saline groups, # Denotes p < 0.05 vs. nicotine withdrawn WT mice.
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Figure 7. Number of transitions of the LDB test during nicotine withdrawal.
Mice were chronically infused with saline or nicotine (12 or 24 mg/kg/day) for 14 days.
Spontaneous nicotine withdrawal was induced on day 15 and the LDB test was performed.
Along with the time spent in the light side, number of transitions between the dark and light
side was recorded. A) Number of transitions on days 1, 2 and 5 after removal of minipumps in
C57BL/6J mice (n=10/per group). B) Number of transitions on day 2 of β2 KO mice (n=8/per
group) C) Number of transitions on day 2 of α6 KO mice (n=8). Each point represents the
mean ± S.E.M. of 8-10 mice per group.
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D. Discussion

In this study, we established spontaneous nicotine withdrawal in mice model. In that
regard, we measured two crucial affective signs (the anhedonia and anxiety) that occur during
nicotine withdrawal in humans (Dawkins et al., 2007; Cook et al., 2014; American Psychiatric
Association, 2000; Hughes, 2007) and rodents (Al-Adawi and Powell, 1997; Dawkins et al.,
2006; Powell et al, 2002; Powell et al, 2004: Jackson et al., 2009b). We used sucrose preference
test as new assay to evaluate the anhedonia-like symptom in mice. We found that spontaneous
nicotine withdrawal significantly produced a sucrose preference reduction in C57BL/6J mice
in a time- and dose-related manner (12 and 24 mg/kg/day of nicotine). According to the time
course results, the attenuation of the sucrose preference occurred at day 1 after removal of
minipumps and continued for 4 days (Fig. 1). However, chronic nicotine exposure did not alter
the sucrose preference compared with their vehicle-treated counterparts (Fig. 2) suggesting
that the sucrose preference reduction is a result of nicotine withdrawal. The decrease in sucrose
preference observed in our studies was not due to nicotine-induced taste aversion since
nicotine-dependent mice did not differ from their saline counterparts in saccharine preference
(Fig. 3). Saccharine and sucrose both are sweet substances, but saccharine is deprived from a
caloric confound that is in the sucrose, which is naturally occurring carbohydrate. We
performed the saccharine preference as a control experiment to control for taste aversion during
nicotine withdrawal. In addition, the decrease in responding for positive affective stimuli
observed in the sucrose preference test is probably not due to food consumption-related effects
during nicotine withdrawal, because nicotine did not affect sucrose preference during chronic
nicotine exposure (Fig. 2). Furthermore, no significant increase in body weight in nicotineinfused mice were observed after minipump removal (Data not shown).
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Our results in the sucrose preference test are in agreement with two previous studies
that used ICSS to evaluate the reduction in rewarding effects and decrease in responding for
positive affective stimuli during nicotine withdrawal in C57BL/6J mice (Stoker et al., 2008;
Johnson et al., 2008). In Johnson et al., (2008), the results were very similar to our sucrose
preference results in terms of dose of nicotine and time course of withdrawal. However, in
Stoker et al., (2008), the change in ICSS thresholds or latencies occurred at a higher dose of
nicotine (40mg/kg/day) than used in the current study and continued for a shorter period of
time.
The sucrose preference of β2 and α6 WT mice was significantly attenuated 48 hrs after
removal of nicotine minipumps, while nicotine withdrawn KO mice did not exhibit a reduction
in sucrose preference (Fig. 4). The results of β2 KO mice were consistent with Stoker et al.
(2015), which used ICSS to measure the reduction in responding for positive affective stimuli
in the same nicotine withdrawn mutant mice. While our study is the first to measure decrease
in responding for positive affective stimuli using the sucrose preference test in α6 KO mice,
the results were consistent with the role of α6 nicotinic subunits in other affective signs
(Jackson et al., 2009a). In addition, our sucrose preference test results were consistent with
other well-established affective symptoms. A previous report demonstrated that other affective
behaviors of nicotine withdrawal (i.e., conditioned placed aversion and reduction in time spent
in the open arm in the Elevated Plus Maze) were also absent in β2 KO mice (Jackson et al.,
2008).
Importantly, attenuation of sucrose preference as an indication of decrease in
responding for positive affective stimuli during nicotine withdrawal is consistent with our
findings of other emotional behaviors, such as an attenuation in the time spent in the light side
of the LDB. Anxiety is another affective symptom of nicotine withdrawal in humans.
(American Psychiatric Association, 2000; Hughes, 2007). The time course of time spent in the
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light side in C57BL/6J mice undergoing nicotine withdrawal was similar to the sucrose
preference results. A significant reduction in time spent in light side in the LDB occurred at 48
hrs and dissipated on day 5 after minipump removal (Fig. 3). Consistent with the sucrose
preference in KO mice, the time spent in the light side was unaffected in β2 and α6 KO mice
at day 2 (Fig. 6). Our findings in LDB were consistent with previous work with the same
apparatus (Jonkman et al., 2005) and another test that measures the reduction in time spent in
open arm, the Elevated Plus-Maze Test (Jackson et al., 2008; Jackson et al., 2009b; Zhao-Shea
et al., 2015).
One of the limitations of our study is the use of passive (non-contingent) nicotine
exposure via subcutaneous osmotic minipumps. However, our results were consistent with
findings of previous studies that used active (contingent) design to provide nicotine in ICSS
(Stolker et al., 2008; Johnson et al., 2008). In addition, this study did not test for sex differences,
which is an important aspect of nicotine withdrawal.
Collectively, our results show that the sucrose preference test and LDB can be used to
evaluate nicotine withdrawal affective signs in mice. The findings of the sucrose preference
test were consistent with the results of ICSS and demonstrated similar phenotypes and nicotinic
receptor mechanisms. These new findings highlight the usefulness of the sucrose preference
test for the study of the neurobiological and pharmacological mechanisms of reduction of
responding for positive affective stimuli that occur during nicotine withdrawal. This test could
be a useful tool for investigating pharmacological and behavioral interventions for nicotine
dependence.
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CHAPTER THREE

Characterization of the Impact of paclitaxel on nicotine withdrawal in mice

A- Introduction

Tobacco dependence is a chronic, relapsing disorder. This type of dependence is
represented by compulsive drug-seeking and drug-taking behaviors. These behaviors are
critical characterizations of substance abuse (Weiss et al., 2006). Therefore, there are many
smokers (healthy population) who attempt to quit, but most of them relapse within weeks after
abstinence. In cancer populations, while a high percentage of cessation rates occur after cancer
diagnosis and treatment, most of these cancer survivors relapse within 2 to 3 years after
cessation. The reasons and mechanisms responsible for this high relapse are not clear. Many
factors including social, behavioral, genetics and biological determinants may play a role in
this phenomenon. One study in cancer patients reported that nicotine withdrawal was more
intensive in terms of anxiety and craving in smoking relapsers in comparison to abstainers
(Gritz et al., 2006). This is important since nicotine withdrawal, the primary negative reinforcer
that strengthens nicotine dependence, is one of the primary causes of high tobacco relapse rates
in healthy adults (Le Foll and Goldberg, 2009).
We recently reported that paclitaxel induced affective-like behavioral deficits (anxiety,
anhedonia and depression- like behaviors) after repeated administration in mice (Toma et al.,
2017). We also found that paclitaxel induced anxiety and anhedonia-like signs in mice in a
time-dependent manner. In addition to long-term cold and mechanical allodynia, paclitaxel
produced anxiety-like behaviors at 3 weeks, 6 weeks and 9 weeks post- treatment. While
anhedonia-like signs appeared during and early after paclitaxel injections, it dissipated shortly
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after (Toma et al., 2017). We were therefore hypothesized that paclitaxel treatment may worsen
nicotine withdrawal in a time-dependent manner.
The current study characterized the effect of anticancer drug, paclitaxel on the nicotine
withdrawal signs using different behavioral assays. We exposed mice to chronic nicotine by
implanting subcutaneous infused minipumps and testing them for withdrawal intensity at early
and late time points after paclitaxel administration. Several measures were conducted to
evaluate the spontaneous nicotine withdrawal signs such as Light Dark Boxes to investigate
the anxiety-like behaviors. We also adapted sucrose preference test to assess the anhedonialike symptoms. Physical signs (somatic signs as well as hyperalgesia) during nicotine
withdrawal were evaluated as well. The findings of this study will advance our understanding
of the possible impact of chemotherapy on nicotine dependence.
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B- Materials and Methods

Animals
8-week-old male C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor,
ME). Mice were housed four per cage with ad libitum access to food and water on a 12-h light
cycle in a humidity and temperature controlled vivarium that was approved by the Association
for Assessment and Accreditation of Laboratory Animal Care. Mice received corn cob bedding
and were fed Envigo Teklad mouse/rat diet 7102 (LM-485). Experiments were performed
during the light cycle and were approved by the Institutional Animal Care and Use Committee
of Virginia Commonwealth University and followed the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.

Drugs
-)-(Nicotine hydrogen tartrate [(-)-1-methyl-2-(3- pyridyl) pyrrolidine (þ)-bitartrate], sucrose
was purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Nicotine was dissolved in
sterile physiological saline (0.9% sodium chloride). Nicotine (12 and 24 mg/kg/day) was
infused through 14-day subcutaneous osmotic minipumps (model 2002, Alzet, Palo Alto, CA,
USA). The doses were expressed as the free base of the drug. The doses were used according
to the previous literature (Damaj et al., 2003; Salas et al., 2004). Sucrose (2%) were dissolved
in water and given orally in the two-bottle choice procedure. Paclitaxel were purchased from
Tocris (Bristol, United Kingdom) and was dissolved in a mixture of 1:1:18 [1 vol ethanol/1 vol
Emulphor-620 (Rhone-Poulenc, Inc., Princeton, NJ)/18 vol distilled water]. Four injections of
paclitaxel (every other day) were administered intraperitoneally (i.p.) in a volume of 1 ml/100
g body weight. The nicotine withdrawal assessments were conducted at two different time
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points following paclitaxel administration: early time point which was 3 days after completion
of paclitaxel injections and late time point which was 70 days post paclitaxel treatment
regimen. In the clinic, low-dose paclitaxel treatment regimen is administering 80 mg/m2
intravenously once per week; the duration of treatment depends on disease progression and
limiting toxicity (Seidman et al., 2008). To approximate this low-dose regimen, our
experiments had i.p. injections of 8 mg/kg paclitaxel every other day for a total of four
injections (1 cycle, cumulative dose is 32 mg/kg), resulting in a cumulative human equivalent
dose of 28.4-113.5 mg/m2 (Reagan- Shaw et al., 2007). A low-dose regimen (8 mg/kg, 1 cycle)
results in long-term mechanical allodynia, which better represents the clinical manifestation of
peripheral neuropathy and allows for affective-related behavioral measures to not be obscured
by severe motor deficits and weight loss.

Withdrawal Induction
C57Bl/6J mice were anesthetized using isoflurane/oxygen vapor mixture (1–3%). After that
the animals were implanted subcutaneously with Alzet osmotic minipumps for 14 days [Model
2002]. Alzet minipumps were filled with either (-) nicotine or saline solutions and inserted by
making incision parallel to the spine at shoulder level of the mouse. The wound was closed
using wound clips then the mice were put in surgery room for recovery before using them in
experiments. Post-operative care was done for 14 days of observation the animals daily. For
all of the procedures, the dose of nicotine was 24 mg/kg/day and it was calculated according
to the mouse weight and number. This dose was used according to the previous literature which
indicated that 24mg/kg/day induce nicotine dependence in mice (Damaj et al., 2003; Salas et
al., 2004; Jackson et al., 2008). For sake of nicotine withdrawal studies, mice were exposed to
nicotine for 14 days. At day 15 the spontaneous nicotine withdrawal was done by removing
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the minipumps under isoflurane anesthesia in aseptic surgical conditions. 24 hr later, the
physical (somatic signs and hyperalgesia) were measured. For affective component (anxiety
and anhedonia-related signs), the assessment performed 48hr after induction of nicotine
withdrawal.
Assessment of nicotine withdrawal signs:
The observation of somatic signs was performed at twenty-four hours after minipump removal.
Animals were acclimated to the plastic cylinders that used for observations of somatic signs
for time period of 30 min. Mice were then assessed in Light dark boxes for 5 min, evaluated
for hyperalgesia using the hot plate and finally the animals’ sucrose preference were
measured.

Somatic Signs. Using clear activity Cages, C57BL/6J mice behavior after removal of
minipumps was observed for a duration of 20 min. The scored somatic signs included head
shakes, paw tremors, retropulsion, writhing, scratching, backing, piloerection, and Straub tail.
For each observation the cage bedding was changed. Somatic signs were calculated as the mean
± S.E.M. number of signs shown by mice during the 20-min observation interval.

Hyperalgesia: The evaluation of Hyperalgesia was done using thermal pain model, hot-plate
test. Hot-plate apparatus is a rectangular heated surface surrounded by 10-cm wide glass
cylinder. To measure the thermal pain sensitivity, the surface of the hot plate is heated to 52.5
ºC. The mouse is placed on the testing apparatus and the manual timer is started. The latency
from putting the animal over the hot plate until jumping or paw-licking was recorded.
Sucrose Preference and Light Dark Box Tests were performed as described (Page 27-29) in
previous chapter.
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Figure 8. Schematic of paclitaxel treatment regimen.
Paclitaxel (8 mg/kg i.p) or Vehicle [Ethanol/emulphor/saline (1:1:18)] were injected every
other day for one week (one cycle of paclitaxel). A total of 4 injections and the cumulative
dose was 32 mg/kg (i.p.). The testing of all of the nicotine withdrawal behaviors was conducted
at two time points: Early time point which is 14 days post completion of paclitaxel treatment
regimen versus late time point (70 days following completion of paclitaxel administration).
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Determination of plasma nicotine levels
To measure plasma nicotine levels in the nicotine withdrawal studies, blood samples were
drawn by cardiac puncture. Nicotine levels in adult male C57BL/6J mice were determined after
pre-treatment with vehicle or paclitaxel (8mg/kg/day). Paclitaxel was administered according
to the regimen described above. On day 56 after the last paclitaxel injectuion, mice were
implanted with subcutaneous osmotic nicotine (24mg/kg/day) minipumps for 14 days. At day
15 the minipumps were removed and immediately the blood was collected by cardiac puncture.
Directly afterwards the plasma samples were obtained by centrifugation at 3000 x g for 10 min
and frozen at –80°C until analysis. To measure total nicotine levels (free and glucuronides),
the samples were incubated with β-glucuronidase at a final concentration of 5 mg/ml in 0.2 M
acetate buffer, pH 5.0, at 37°C overnight. After incubation the samples were processed and
analyzed for nicotine levels by LC/MS/MS as described in Alsharari et al., (2015).
Nicotine LC/MS/MS analysis
To a 200 μl aliquot of plasma, 50 μl of internal standard containing 50 ng of nicotine-d4 in
methanol was added with mixing. Then 100 μl of 5 M ammonium hydroxide was added to each
sample followed by 2 ml methylene chloride. The samples were mixed for 2 min and then
centrifuged for 5 min at 3000 rpm at a temperature of 4°C. The organic layer was transferred
to a clean test tube. The aqueous phase was extracted twice more with 2 ml of methylene
chloride. The organic phases were combined and 500 μl of 25 mM HCl in methanol was added.
Samples then were evaporated to dryness under a gentle stream of nitrogen. They were
reconstituted with 100 μl of mobile phase and placed in auto-sample (LC/ MS/MS) vials for
analysis. Instrumental analysis. The LC/MS/MS system used was an Applied Bio systems 3200
Qtrap with a turbo V source for TurbolonSpray with a Shimadzu SCL HPLC system controlled
by Analyst 1.4.2 software. The chromatographic separation was performed using an Hypersil
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Gold, 3 mm X 50 mm, 5 micron (Thermo Scientific, USA). The mobile phase contained 10
mM ammonium formate; methanol (10:90 V/V) and was delivered at a flow rate of 0.5 ml/
min. The acquisition mode used was multiple reaction monitoring (MRM) in a positive mode.
Transition ions monitored for nicotine (163>130; 163>117) and nicotine-d4 (167>134). The
total chromatographic separation time for each extract injection was 2 min. A calibration curve
ranging from 12.5 ng/ml to 500 ng/ml was constructed for each compound based on linear
regression using the peak area ratios of the drug to its deuterated internal standard. This
experiment was adapted from (Alsharari et al., 2015).
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Statistical analysis

Data were analyzed using the GraphPad software version 6.0 (GraphPad Software, Inc., La
Jolla, CA) and expressed as the mean ± S.E.M. Ordinary two-way analysis of variance
(ANOVA) followed by the Tukey multiple comparisons test was used in order to evaluate the
effect of paclitaxel on nicotine withdrawal-induced somatic and affective responses in various
assays. All studies were analyzed via ANOVA with nicotine (or saline) and Paclitaxel (or
vehicle) as the between subject factor. To determine if there was a paclitaxel effect on nicotine
plasma level, results with the paclitaxel nicotine treated cohorts were compared to the vehicle
nicotine treated cohorts with an unpaired two-tailed t-test. Comparisons were considered
statistically significant when p < 0.05.
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C. Results

Paclitaxel worsens somatic signs induced by spontaneous nicotine withdrawal

Mice were infused with 24mg/kg/day of nicotine for 14 days. On day 15, the induction of
nicotine withdrawal was performed by removal of subcutaneous minipumps. Nicotine
withdrawal assessment was conducted at two different time points after paclitaxel injection. At
the early time point, (7 days after completion of paclitaxel treatment regimen) a two-way
ANOVA analysis revealed a significant increase in somatic signs in nicotine-withdrawn mice
in comparison to their saline controls [F (1, 36) = 68.14;

p

<

0.0001;

Fig.

9A].

Interestingly, pretreatment with paclitaxel induced a significant increase in expression of
somatic withdrawal signs compared to vehicle-treated mice [F (1, 36) = 4.120;

p = 0.0498;

Fig. 9A]. In addition, the interaction between paclitaxel pretreatment X nicotine treatment was
significant between the same subjects [F (1, 36) = 5.933;

p = 0.0199; Fig. 9A]. Similarly,

nicotine dependent mice showed significantly higher nicotine withdrawal somatic signs when
compared to their saline infused controls [F (1, 36) = 125.9; p < 0.0001; Fig. 9B] at late time
point (mention the day #). Consistent with early time point, paclitaxel treatment regimen
exhibited significant elevation in expression of nicotine withdrawal somatic manifestations at
late time point [F (1, 36) = 14.83;

p = 0.0005; Fig. 9B]. Two-way ANOVA displayed a

significant effect of interaction between 2 different treatments (paclitaxel and nicotine) [F (1,
36) = 30.53;

p < 0.0001; Fig. 9B].
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Figure 9. Effects of anticancer agent, paclitaxel on somatic signs of spontaneous nicotine
withdrawal.
Mice were chronically infused with saline or nicotine (24 mg/kg/day) for 14 days. Minipumps
were removed from mice by surgical incision on day 15. One day after induction of
spontaneous nicotine withdrawal, mice observed for somatic signs for 30 minutes. A) Somatic
signs observations at early time point (15 days following completion of paclitaxel treatment
regimen). B) Somatic signs observations at late time point (70 days after completion of
paclitaxel injections). Each point represents the mean ± S.E.M. of 12 mice per group. * Denotes
p<0.05 vs Vehicle/Saline; # Denotes p<0.05 vs Vehicle/Nicotine.
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Paclitaxel worsens nicotine withdrawal-induced reduction in sucrose preference in a
time-dependent manner

The capacity of paclitaxel to alter nicotine-associated withdrawal signs was further evaluated
with measures of spontaneous withdrawal that encompassed anhedonia-related behaviors. We
measured sucrose preference in mice 48 hrs after minipumps removal. At the early time point
of paclitaxel pretreatment, nicotine (24mg/kg/day) infused groups demonstrated significant
attenuation of sucrose preference when compared to their saline controls [F (1, 36) = 4.557; p
= 0.0397; Fig. 10A]. However, nicotine-dependent mice pretreated with paclitaxel did not
show further decrease in sucrose deficit in comparison to nicotine infused mice pretreated with
vehicle [ F (1, 36) = 4.189;

p = 0.0480; Fig. 10A]. In that regard, significant difference was

found in the interaction between two treatments [F (1, 36) = 5.652; p = 0.0229; Fig. 2A].
Interestingly, two-way ANOVA analysis revealed a significant reduction of sucrose preference
in nicotine treatment [F (1, 36) = 19.45;
pretreatment [F (1, 36) = 22.23;

p < 0.0001; Fig. 10B], after paclitaxel

p < 0.0001; Fig. 10B] at late time point. In addition, the

interaction between paclitaxel pretreatment and nicotine was not significant [F (1, 36) =
0.04024; p = 0.8421; Fig.10B].
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Figure 10. Impact of paclitaxel on spontaneous nicotine withdrawal-induced reduction in
sucrose preference.
Mice were chronically infused with nicotine (24 mg/kg/day) for 14 days. Minipumps were
removed from mice on day 15, and sucrose preference (2%) was performed 48 hrs later. A)
Sucrose preference test was performed at early time point (15 days after paclitaxel exposure).
B) Sucrose preference at late time point (70 days after completion of paclitaxel
administrations). Each point represents the mean ± S.E.M. of 12 mice per group. * Denotes
p<0.05 vs Vehicle/Saline; # Denotes p<0.05 vs Vehicle/Nicotine.
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Paclitaxel attenuated anxiety-like behaviors expressed during nicotine withdrawal

To investigate the effect of paclitaxel on nicotine withdrawal-induced anxiety-like behaviors,
we measured the time spent in the light chamber in nicotine-dependent C57BL/6J mice using
the LDB assay. In this experiment, we used the same cohorts of mice that underwent the
spontaneous nicotine withdrawal assays. Early on, after paclitaxel pretreatment, two-way
ANOVA with Tukey post-hoc test revealed that significant effects for nicotine treatment [F (1,
36) = 34.98; p < 0.0001; Fig. 11A], paclitaxel pretreatment [F (1, 36) = 7.932;

p = 0.0078;

Fig. 11A] and interaction [F (1, 36) = 4.282; p = 0.0457; Fig. 11A]. Similarly, at the late time
point (two months after completion of paclitaxel injections), nicotine withdrawn mice
pretreated with paclitaxel showed significant reduction in time spent in the light side when
compared to nicotine mice that pretreated with vehicle [F (1, 36) = 23.71; p < 0.0001; Fig.
11B]. Also, two-way ANOVA revealed significant enhancement in anxiety-like signs in
nicotine infused mice in comparison to their saline counterparts [F (1, 36) = 22.81; p < 0.0001;
Fig. 11B], while the interaction was not significant [F (1, 36) = 0.6768; p = 0.4161; Fig. 11B].
These findings suggest that treatment with paclitaxel worsened anxiety-like withdrawal
symptoms in both time points .
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Figure 11. Influence of paclitaxel on anxiety-like behavior after induction the
spontaneous nicotine withdrawal.
C57BL/6J mice were chronically infused with nicotine (24 mg/kg/day) for 14 days. Minipumps
were removed from mice on day 15, and the LDB test was performed 48 h later. A) Time spent
in the light side at early time point (15 days after paclitaxel exposure). B) Time spent in the
light side at late time point (70 days after completion of paclitaxel administrations). Each point
represents the mean ± S.E.M. of 12 mice per group. * Denotes p<0.05 vs Vehicle/Saline; #
Denotes p<0.05 vs Vehicle/Nicotine.
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Paclitaxel did not alter nicotine withdrawal-induced hyperalgesia

To determine possible effects of paclitaxel on nicotine withdrawal-induced hyperalgesia, we
tested nicotine dependent mice pretreated with paclitaxel in the hot plate test. At the early time
after pretreatment with paclitaxel, nicotine-infused mice showed significant attenuation of hot
plate latencies (measure of hyperalgesia) in comparison to their saline counterparts [F (1, 36)
= 15.22;

p = 0.0004; Fig. 12A]. Interestingly, pre-exposure to paclitaxel was ineffective

at further reducing hot plate latencies in nicotine-withdrawn mice [F (1, 36) = 0.02537; p =
0.8743; Fig. 12A]. Furthermore, the interaction between paclitaxel pretreatment and nicotine
treatment was not significant [F (1, 36) = 0.9679;

p = 0.3318; Fig. 12A]. Similarly, two-

way ANOVA with Tukey post-hoc test demonstrated no significant effects for paclitaxel
pretreatment at late time point [F (1, 36) = 0.1021; p = 0.7511; Fig. 12B], while withdrawal
from nicotine versus saline showed significant decrease in hyperalgesia [F (1, 36) = 15.47;
p = 0.0004; Fig. 12B]. There was not a significant interaction between paclitaxel and
nicotine [F (1, 36) = 0.9679; p = 0.3318; Fig. 12B].
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Figure 12. The effect of paclitaxel on hyperalgesia during spontaneous nicotine
withdrawal.
Mice were chronically infused with saline or nicotine (24 mg/kg/day) for 14 days. On day 15
mice underwent spontaneous nicotine withdrawal and the Hot Plate test was performed at days
1 after removal of minipumps. A) Hot Plate latency (measure of hyperalgesia) at early time
point (15 days after paclitaxel exposure). B) Hot Plate latency at late time point (70 days after
completion of paclitaxel administrations). Each point represents the mean ± S.E.M. of 12 mice
per group. * Denotes p<0.05 vs Vehicle/Saline.
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Effect of paclitaxel on the nicotine plasma level after chronic nicotine treatment

We tested the effect of paclitaxel on plasma nicotine and cotinine levels after chronic
administration of nicotine (24 mg/kg/day for 14 days) in mice pretreated with vehicle or
paclitaxel 70 days after completion of chemodrug treatment. According to an unpaired twotailed t-test, pretreatment with paclitaxel did not induce significant change in nicotine plasma
[t=0.8509, df =7; p= 0.423; Fig. 13A] and cotinine plasma levels [t=0.4963, df=8; p= 0.6331;
Fig. 13B]. These interesting finding suggested that paclitaxel did not alter the metabolism of
nicotine.
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Figure 13. Impact of paclitaxel on nicotine pharmacokinetics.
Mice were pretreated with either paclitaxel (8 mg/kg/day i.p.) or vehicle (1:1:18) and kept 55
days after completion of paclitaxel treatment regimen. Fifty-five days after completion of
paclitaxel treatment regimen, mice were then implanted with osmotic subcutaneous nicotine
(24mg/kg/day) minipumps for 14 days. At day 15 the minipumps were removed and
immediately the blood samples were drawn by cardiac puncture. A) Nicotine level and B)
cotinine level. Each point represents the mean ± SEM of n =5 mice per group.
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Discussion

This is the first report demonstrating the ability of an anticancer agent, paclitaxel to
alter nicotine withdrawal manifestations in rodents. While no effect of paclitaxel was observed
on nicotine withdrawal-induced hyperalgesia (Fig. 12), as measured in the hot plate test,
paclitaxel worsened the somatic and anxiety-like signs in our mouse model both times after the
chemodrug treatment. However, we observed a time-dependent effect of paclitaxel on nicotine
withdrawal in the sucrose preference test. Paclitaxel worsened nicotine withdrawal-induced
reduction in sucrose preference at the late time point only. These data suggest that paclitaxel
produced overall exacerbation in nicotine withdrawal signs.
Our data on paclitaxel extends earlier work from our lab that reported paclitaxel
induced sensory and affective deficit in C57BL/6J mice (Toma et al., 2017). Paclitaxel was
found to significantly attenuate the time spent in light side at 3, 6, and 9 weeks post paclitaxel
treatments (Toma et al., 2017), which is consistent with our findings in paclitaxel at the early
and late time points after its administration. In addition, paclitaxel by itself caused anhedonialike response shortly after completion of its treatment regimen (Toma et al., 2017). These
results are in agreement with our findings in the sucrose preference test, which demonstrated
anhedonia-like sign early and late time points post paclitaxel administration. However,
paclitaxel by itself did not elicit hyperalgesia at early and late time points following initiation
of paclitaxel treatment regimen. Furthermore, several studies reported that cancer patients who
are treated with chemotherapy have CIPN combined with insomnia, depression and anxiety
(Eckhoff et al., 2015; Bao et al., 2016; Massie, 2004; Love et al., 1982; Reeves et al., 2012;
Thornton et al., 2008). This neuropathy has a high prevalence rate in cancer patients and
survivors; up to 80% of patients experience CIPN during and after treatment with paclitaxel
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(Sisignano et al., 2014). CIPN develops within weeks or months after beginning the treatment
regimen of paclitaxel and may persist from one month to 5 years after paclitaxel therapy
completion (Reeves et al., 2012; Bao et al., 2016). Thus, we chose for our investigation two
important time points reflecting the early and long term sensory and affective deficits in cancer
patients and survivors.

Several possible mechanisms could mediate the enhancement of nicotine withdrawal
signs by paclitaxel observed in our studies. The most obvious one is the possible alteration of
nicotine distribution and metabolism by paclitaxel. Paclitaxel may dysregulate cytochrome
P450 2A6 (CYP2A6), the main metabolizing enzyme of nicotine and subsequently enhanced
plasma nicotine levels leading to an increase of nicotine withdrawal intensity (Ray et al., 2009).
However, our data showed that paclitaxel did not alter the nicotine and cotinine levels
suggesting that pharmacokinetic factors play little role in this increase. However, it is possible
that paclitaxel could enhance nicotine brain penetrability without affecting plasma nicotine
levels.
A possible mechanism underlying the increase in nicotine withdrawal intensity is the
induction of an aversive state by paclitaxel. Animal and human studies demonstrated that
paclitaxel induced neuropathic pain (CIPN) (Mori et al., 2014; Neelakantan et al., 2016; Toma
et al., 2017). This neuropathic pain induced a negative aversive state (King et al., 2009), which
may exacerbate the physical and affective signs of nicotine withdrawal.
Studies revealed that low levels of paclitaxel can penetrate into the central nervous
system (Gangloff et al., 2005; Kemper et al., 2003), triggering various changes in the neuronal
transmission, in particular neuronal mechanisms mediating nicotine withdrawal. For example,
nicotine withdrawal is thought to produce a hypodopaminergic state indicated by diminished
dopamine levels in the NAc of rats (Markou, 2008; Foll and Goldberg, 2009; Takahashi et al.,
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1995; Carboni et al., 2000), attenuation in dopamine release in the NAc (Zhang et al., 2012),
and brain reward deficits (Epping-Jordan et al., 1998). It is possible that paclitaxel pretreatment
regulated dopamine signaling in brain regions that are involved in mediating the affective
symptoms of nicotine withdrawal. On the other hand, kappa receptors (KOR) signaling may
play a part in inducing this hypofunctional dopaminergic state of nicotine withdrawal
syndrome. KOR system has been associated with mood and depressive-like states (Mague et
al., 2003; Bruchas et al., 2010). Activation of KOR decreases dopamine levels in the NAc by
blocking dopamine release and enhancing dopamine reuptake (Thompson et al., 2000; Chefer
et al., 2005). Paclitaxel may enhance the KOR signaling, which in turn could increase the
production of dynorphin and inhibit DAR transmission leading to severe affect deficit during
nicotine withdrawal.
Furthermore, paclitaxel may modulate the primary pharmacological targets of nicotine,
in particular nicotinic receptors (nAChRs). Paclitaxel may regulate the expression of brain
nAChRs leading to a change in nicotine withdrawal symptoms. Several nAChRs subunits were
shown to mediate the affective signs of nicotine withdrawal. For example, β2 nAChR submits
involved in nicotine withdrawal induced-anxiety and anhedonia-like behaviors (Jackson et al.,
2009b; Alkhlaif et al., 2017). Paclitaxel may modulate the expression and/or the function of
β2-containing nAChR subtypes or modulate the upregulation of these receptors during chronic
nicotine exposure. Previous theories suggested an upregulation of surface α4β2 nicotinic
receptors induced by receptor desensitization after chronic exposure to nicotine (Govind et al.,
2009; Benowitz et al., 2010; Wang and Sun, 2004). Paclitaxel could also affect the expression
of other nAChR subunits that were also involved in mediating the nicotine withdrawal somatic
and affective signs such as α3 (Jackson et al., 2014), α5 (Jackson et al., 2008; Salas et al.,
2009), α2 (Salas et al., 2009), β4 (Stoker et al., 2012; Jackson et al., 2014) and α7 nicotinic
subunits (Stoker et al., 2012; Jackson et al., 2008; Grabus et al., 2005).
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Finally, paclitaxel may induce changes in nicotine withdrawal signs through
neuroinflammatory or glial mechanisms in the brain resulting in a more intense nicotine
withdrawal.
Taken all together, our results suggested that antineoplastic agent, paclitaxel
exacerbated the nicotine withdrawal symptoms in C57BL/6J mice. These data may help
explain that smoking rates and relapse in cancer patients since nicotine withdrawal, the primary
negative reinforcer that strengthens nicotine dependence, is one of the primary causes of high
tobacco relapse rates (Le Foll and Goldberg, 2009). Our results in this preclinical study
highlight the impact of chemotherapy in physical and mood- related changes during nicotine
withdrawal.
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CHAPTER FOUR

Impact of paclitaxel on nicotine reward using the conditioned place preference test

A- Introduction

Although cigarette smoke has been implicated in a causal relationship with various
types of cancers (Tong et al., 1996; Dresler et al., 1996; Videtic et al., 2003), around 62% of
all cancer patients are current smokers, recent quitters, or former smokers. While most patients
who are smokers are motivated to quit after cancer diagnosis, 25 -30% of these patients
continue to smoke (Demark-Wahnefried et al., 2005; Peppone et al., 2011; Karam-Hage et al.,
2016). Furthermore, most quitters relapse after 2-3 years of post-chemotherapy and rejoin the
general population in smoking rates (Cooley et al., 2009; Karam-Hage et al., 2016). Indeed,
this smoking rate in cancer populations raises clinicians’ concern, because several studies
revealed that the perpetuation of smoking in cancer populations may impair healing, attenuate
the efficacy of chemotherapy, decrease quality of life of patients, increase the disease
complications and diminish survival rates (Yoshino et al., 2007; Johnston-Early et al., 1980;
Khuri et al., 2001). The factors that involved in persistence and relapse of nicotine dependence
in cancer patients are poorly understood. Human studies suggested that among the factors that
could be responsible for the continuation of tobacco smoking in cancer patients and survivors
are tumor site, impact of cancer therapy and disease prognosis (Gritz et al., 1990; Ostroff et al.,
1995; Cox et al., 2002). Thus, there is a need for a better understanding of the role of
chemotherapy in nicotine addiction. In this study, we focused on the impact of the
chemotherapeutic agent, paclitaxel on nicotine reward, an important aspect of smoking
dependence (Stolerman et al., 1991). Indeed, the influence of paclitaxel on nicotine reward and
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reinforcement was not reported in human and animal literature. Two recent animal studies
explored the effect of paclitaxel on the reinforcement as well as rewarding properties of
morphine and other opioids (Neelakantan et al., 2016; Mori et al., 2014). These studies reported
that paclitaxel did not alter morphine reward and reinforcement in CPP and i.v. selfadministration paradigms in rodents. However, in both studies, animals were tested right after
paclitaxel treatment protocol. Since our withdrawal studies (Chapter 3) showed a timedependent effect of paclitaxel on nicotine withdrawal, we evaluated nicotine conditioned
reward at multiple time points post paclitaxel administration in the CPP test. The conditioned
place preference test is a well-known paradigm to measure the conditioned reward of drugs of
dependence such as nicotine (Brunzell et al., 2015; Walters et al., 2006; Grabus et al., 2006;
Neugebauer et al., 2011).
We therefore assessed the time-course and dose-dependency of nicotine CPP in
C57BL/6J mice. Studies were designed to answer the following questions: (A) Does paclitaxel
treatment alters nicotine reward in a time-dependent manner? (B) Is this effect selective to
nicotine or does it affect other drugs of abuse such as morphine and natural reward
mechanisms? These experiments performed at two time points; the early and late time points
post paclitaxel exposure.
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B- Materials and methods
Animals
8-week-old male C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor,
ME). Mice were housed four per cage with ad libitum access to food and water on a 12-h light
cycle in a humidity and temperature controlled vivarium that was approved by the Association
for Assessment and Accreditation of Laboratory Animal Care. Mice received corn cob bedding
and were fed Envigo Teklad mouse/rat diet 7102 (LM-485). Experiments were performed
during the light cycle and were approved by the Institutional Animal Care and Use Committee
of Virginia Commonwealth University and followed the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.
Drugs
(-)-Nicotine hydrogen tartrate [(-)-1-methyl-2-(3- pyridyl) pyrrolidine (þ)-bitartrate], sucrose
was purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA). Nicotine was dissolved in
sterile physiological saline (0.9% sodium chloride). Nicotine (0.1, 0.5, 1, 2 mg/kg/day) was
injected subcutaneously. The doses were expressed as the free base of the drug. The doses were
used according to the previous literature (Grabus et al., 2006; Sanjakdar et al., 2015). Morphine
was provided as part of the drug supply program from the National Institute for Drug Abuse
(Rockville, MD, USA). Paclitaxel was dissolved in a mixture of 1:1:18 [1 vol ethanol/1 vol
Emulphor-620 (Rhone-Poulenc, Inc., Princeton, NJ)/18 vol distilled water]. Four injections of
paclitaxel (every other day) were administered intraperitoneally (i.p.) in a volume of 1 ml/100
g body weight. The nicotine conditioned place preference assessments were conducted at two
different time points following paclitaxel administration: early time point which was 7 days
after completion of paclitaxel injections and late time point which was 70 days post paclitaxel
treatment regimen. In clinic, low-dose paclitaxel treatment regimen is administering 80 mg/m2
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intravenously once per week; the duration of treatment depends on disease progression and
limiting toxicity (Seidman et al., 2008). To approximate this low-dose regimen, our
experiments had i.p. injections of 8 mg/kg paclitaxel every other day for a total of four
injections (1 cycle, cumulative dose is 32 mg/kg), resulting in a cumulative human equivalent
dose of 28.4-113.5 mg/m2 (Reagan- Shaw et al., 2007). A low-dose regimen (8 mg/kg, 1 cycle)
results in long-term mechanical allodynia, which better represents the clinical manifestation of
peripheral neuropathy, and allows for affective-related behavioral measures to not be vanished
by severe motor deficits and weight loss. Food used to induce place preference in mice was
Sucrose Chocolate Pellets purchased from Bio.Serve- Nutritional and the ingredient label on
the package reads: protein 18.4%, fat 5.5%, fiber 4.6%, carbohydrate 59.1% and ash 6.5%.

Methods
Nicotine and morphine Conditioned Place Preference studies
An unbiased CPP paradigm was performed, as we previously described (Jackson et al., 2017).
Briefly, the CPP apparatus consisted of three chambers in a linear arrangement (Med
Associates, St Albans, VT). The CPP apparatus was (MedAssociates, St. Albans, VT,
ENV3013) composed of white and black chambers (20×20×20 cm each), which differed in
overall color and floor texture (white mesh or black rod). These chambers were separated by a
smaller gray chamber with a smooth PVC floor. Partitions could be removed to allow access
from the gray chamber to the black and white chambers. On day 1, animals were confined to
the middle chamber for a 5-min habituation and then allowed to freely move between all three
chambers for 15 min. Time spent in each chamber was recorded, and these data were used to
populate groups of approximately equal bias in baseline chamber preference. Twenty min
conditioning sessions occurred twice a day (days 3–5). During conditioning sessions, mice
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were confined to one of the larger chambers. The saline groups received saline in one large
chamber in the morning and saline in the other large chamber in the afternoon. The drug
(nicotine 0.1, 0.5, 1 mg/kg/day s.c. or morphine 1 and 10 mg/kg/day s.c.) group received
treatment in one large chamber and saline in the other large chamber. Treatments occurred in
separate cohorts of mice and they were counterbalanced equally in order to ensure that some
mice received the unconditioned stimulus in the morning while others received it in the
afternoon. The drug-paired chamber was randomized among all groups. Sessions were 4 hrs
apart and conducted by the same investigator. Mice were pretreated with paclitaxel and the
CPP experiments performed at two time points; the early time point was 7 days after
completion of paclitaxel treatment regimen, and late time point was 70 days after completion
of paclitaxel injections. On test day (day 5), mice were allowed access to all chambers for 15
min in a drug free state. The preference score was calculated by determining the difference
between time spent in the drug paired side during test day versus the time in drug paired side
during the baseline day.
Conditioned Place Preference for Food Reward
For studies involving food conditioned place preference, we followed the CPP procedure stated
in the above paragraph, with a few minor modifications. Briefly, mice underwent
preconditioning on day 1 (baseline) and were divided into groups of equal bias, as described
above, and were then immediately after baseline exposed to sucrose chocolate pellets (palatable
chows) for the next 6 h in their home cages to minimize the neophobia within the test
environment, which can impair conditioned responding (Sharma et al. 2012). The conditioning
days followed the same experimental design as described in the paragraph above, but mice
received sucrose chocolate (or standard chow pellet) instead of drug (or saline), there was two
extra days of conditioning, and each conditioning session lasted for 40 min. Control groups
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received the standard chow pellet in both compartments. This study was adapted from
Sanjakdar et al., (2006).

76

Figure 14. Schematic of paclitaxel treatment regimen.
Paclitaxel (8 mg/kg i.p) or Vehicle [Ethanol/emulphor/saline (1:1:18)] were injected every
other day for one week (one cycle of paclitaxel), for a total of 4 injections and the cumulative
dose was 32 mg/kg (i.p.). The testing of most of the behaviors in chapter three and four were
conducted at two time points: early time point which was 7 days post completion of paclitaxel
treatment regimen versus late time point which was 70 days following completion of paclitaxel
administration.
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Figure 15. Schematic of conditioned place preference apparatus and protocol. (adapted
from: Calipari et al., 2016)
Mice were confined to the middle chamber for a 5-min habituation and then allowed to freely
move between all three chambers for 15 min (day1, baseline). The conditioning period started
after day one and twenty-minute conditioning sessions occurred twice a day (days 3–5). The
drug free test day followed the conditioning days and it is similar to the baseline day, which
included counting the time spent in each compartment. The preference score was calculated by
subtraction of the time spent in the drug paired side during test day from the time spent in the
drug paired side during the baseline day.
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Determination of plasma nicotine levels
To measure plasma nicotine levels in the acute nicotine studies, blood samples were drawn by
cardiac puncture at two different time point. Nicotine levels in adult male C57BL/6J mice were
determined after pre-treatment with vehicle or paclitaxel (8mg/kg/day). Paclitaxel was
administered according to low dose treatment regimen. We kept these mice for 70 days
following completion of paclitaxel treatment regimen. At day 70, the mice were injected
nicotine (1mg/kg/day). Blood was collected by cardiac puncture at two different time points
post nicotine injection (5 and 30 min). The rest of the experiment was previously described in
chapter three.

Acute nicotine assessment
Naïve C57Bl/6J mice were injected i.p. with vehicle or paclitaxel cycle (32 mg/kg total) 70
days prior to a single s.c. injection with nicotine or saline. Antinociception using the hot-plate
test and changes in locomotor activity were measured 5 min post nicotine administration and
changes in body temperature was examined 30 min following nicotine or saline injection.
These behavioral assays were adapted from Jackson et al., (2013).

Antinociception
Antinociception (n= 12- 16 per group) was assessed by the hot plate, which is a rectangular
heated surface surrounded by plexiglass and maintained at 55°C. The device is connected to a
manually operated timer that records the amount of time the mouse spends on the heated
surface before showing signs of nociception (e.g. jumping, paw licks). A control response (812 s) was determined for each mouse before treatment, and test latency was determined 5 min
after nicotine administration at doses of 1 and 2 mg/kg, s.c. The timer has an automatic cut-off
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of 20 seconds to avoid tissue damage. The hot plate response was calculated as percentage of
maximum possible effect (% MPE), where % MPE = [(test - control)/ (20 - control)] × 100.

Body temperature
Rectal temperature (n= 12-16 per group) was measured by a thermistor probe (inserted 24 mm)
and digital thermometer (YSI Inc., Yellow Springs, OH). Readings were taken just before and
at 30 min after nicotine injection (1 and 2 mg/kg, s.c.). The difference in rectal temperature
before and after treatment was calculated for each mouse. The ambient temperature of the
laboratory varied from 21-24°C from day to day.

Locomotor activity
Mice (12-16 per group) were placed into individual photocell activity cages (28 × 16.5 cm;
Omnitech, Columbus, OH) 5 min after saline or nicotine (1.5 mg/kg, s.c.) administration.
Interruptions of the photocell beams (two banks of eight cells each) were then recorded for the
next 10 min. Data are expressed as number of photocell interruptions.
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Statistical analysis
Data were analyzed using the GraphPad software version 6.0 (GraphPad Software, Inc., La
Jolla, CA) and expressed as the mean ± S.E.M. Two-way ANOVA followed by the Tukey
multiple comparisons test was used in order to evaluate the significant attenuation of dose
response of nicotine or morphine CPP by paclitaxel pretreatment. For acute sensitivity tests,
Two-way ANOVA followed by the Tukey multiple comparisons was used in order to evaluate
attenuation of acute responses of nicotine by chemotherapeutic agent paclitaxel. Comparisons
were considered statistically significant when p < 0.05.
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C- Results

Paclitaxel blocked the development of nicotine CPP
To determine the effect of chemodrug paclitaxel on the rewarding properties of nicotine, CPP
was conducted at early (7 days after paclitaxel treatment regimen) and late time points (70 days
post paclitaxel administration) for nicotine dose (0.5mg/kg/day) (Fig.16A, B). The dose
response curve of nicotine (0.1, 0.5 or 1mg/kg/day) in the CPP paradigm was conducted at the
late time point (Fig.16C). Two-way ANOVA revealed significant nicotine (0.5mg/kg/day)
CPP in vehicle pretreated mice at the early time point [F (1, 40) = 16.32; p = 0.0002; Fig.16A]
and at the late time point [F (1, 45) = 25.26; p < 0.0001; Fig.16B]. Furthermore, ordinary
Two-way ANOVA followed by Tukey multiple comparisons test revealed significant nicotine
CPP by doses (0.1, 0.5 and 1 mg/kg/day) (p <0.05) in vehicle pretreated mice comparing to
their saline counterparts (Fig.16C). Two-way ANOVA also demonstrated that pretreatment
with paclitaxel significantly abolished the nicotine (0.5mg/kg/day) conditioned place
preference at the late time point [F (1, 45) = 17.39; p = 0.0001; Fig.16B], but not the early time
point (Fig.16A) (p> 0.05). According to Tukey multiple comparisons test, pretreatment with
paclitaxel also showed no significant reduction of nicotine CPP induced by the doses (0.1 and
1 mg/kg/day) (p> 0.05) (Fig.16C). Paclitaxel did not produce preference or aversion on its own
(p> 0.05).
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Figure 16. Paclitaxel attenuated the conditioned reward effect of nicotine CPP.
Mice were conditioned with either saline or nicotine (0.1, 0.5 and 1 mg/kg; s.c.) for 5 days. A)
Nicotine (0.5mg/kg/day) CPP at early time point (7 days after paclitaxel treatment regimen)
and B) Late time point (70 days post paclitaxel administration). C) Dose response curve of
nicotine in CPP experiment was performed by utilizing 3 doses of nicotine (0.1, 0.5 and
1mg/kg/day) at late time point. * Denotes p<0.05 from vehicle- saline. # Denotes p<0.05 from
vehicle- nicotine. Each point represents the mean ± SEM of n=12-13 mice per group.
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Paclitaxel-induced reward deficit was not specific for nicotine
To test for the behavioral selectivity of paclitaxel on nicotine CPP, paclitaxel was evaluated in
morphine (10mg/kg/day) CPP at the early and late time points (Fig. 17A, B). A dose response
curve of morphine (1, 10mg/kg/day) was also performed in the CPP. According to Two- way
ANOVA, a significant CPP was observed in morphine– conditioned (10 mg/kg/day) mice pretreated with vehicle at the early [F (1, 28) = 19.23; p = 0.0001; Fig17A] and late time points
[F (1, 28) = 22.16;

p < 0.0001; Fig17B]. Similarly, a Tukey multiple comparisons test

revealed significant morphine (1, 10 mg/kg/day) CPP (p <0.05) in vehicle pretreated mice
(Fig.17C). Two-way ANOVA demonstrated that pretreatment with paclitaxel significantly
attenuated the morphine (10 mg/kg/day) conditioned place preference [F (1, 28) = 5.854; p =
0.0223; Fig.17B] at the late time point, but not morphine CPP at the early time point [F (1, 28)
= 0.7853;

p = 0.3831; Fig.17A]. Furthermore, Tukey multiple comparisons test showed

insignificant effect of paclitaxel on morphine (1 mg/kg/day) CPP (p> 0.05) (Fig.17C).
Paclitaxel did not produce preference or aversion on its own (p> 0.05).
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Figure 17. Morphine conditioned place preference was time-dependently diminished by
paclitaxel.
Mice underwent 3 days of conditioning with either s.c. saline or morphine (1, 10 mg/kg/day).
A) Morphine (10mg/kg/day) CPP at early time point (7 days after paclitaxel treatment regimen)
and B) Late time point (70 days post paclitaxel administration). C) Dose response curve of
morphine (1 and 10mg/kg/day) in CPP experiment at late time point. * Denotes p<0.05 from
vehicle-saline. # Denotes p<0.05 from vehicle- morphine. Each point represents the mean ±
SEM of n= 8-12 mice per group.
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Paclitaxel did not affect food-induced CPP
To test whether chemotherapeutic agent paclitaxel alters the associative learning or contextual
and cued CPP memory, we examined conditioned place preference for highly palatable food
as a control experiment. We performed this experiment at the late time point where we found
the significant effect of paclitaxel pretreatment in nicotine and morphine CPP. A Two-way
ANOVA indicated that significant CPP was observed for highly palatable food compared to
standard chow [F (1, 44) = 19.59; p < 0.0001; Fig.18]. Paclitaxel did not significantly alter
food-induced CPP [F (1, 44) = 0.07307; p = 0.7882; Fig.18]. The interaction between palatable
food and the paclitaxel pretreatment was not significantly different [F (1, 44) = 0.07307; p =
0.7882; Fig.18]. This result suggested that attenuation in nicotine and morphine CPP by
paclitaxel was not due to an impairment of contextual memory.
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Figure 18. Paclitaxel did not alter highly palatable food conditioning.
Mice underwent 6 days of conditioning with either sucrose chocolate chows or standard food
chow. High palatable food, sucrose chocolate pellets produced a robust CPP in mice pre-treated
with the vehicle. Two months following paclitaxel (8 mg/kg/day; i.p.) treatment regimen, there
was no significant effect on food-induced CPP. * Denotes p<0.05 from vehicle- standard chow.
Each point represents the mean ± SEM of n=12 mice per group.
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Paclitaxel did not alter the nicotine plasma level after nicotine acute exposure
To test the impact of paclitaxel on nicotine pharmacokinetics, we measured plasma nicotine
and its major metabolite cotinine levels after administration of nicotine in paclitaxel pretreated
mice at 5 and 30 min after nicotine administration at 1 mg/kg, s.c. These mice were pretreated
with either paclitaxel (8 mg/kg/day) or vehicle 70 days before blood collection. We were
interested in collecting the blood samples at the late time point (70 days after completion of
paclitaxel treatment regimen), because the significant effect of paclitaxel was revealed lately
after its administration as seen in nicotine and morphine CPP. For the 5-min time point, an
unpaired two-tailed t-test did not reveal a significant impact of paclitaxel pretreatment on
nicotine plasma [t=0.1598; df=7, p= 0.8776; Fig.19A] and in cotinine plasma levels [t=0.3829
df=7, p= 0.7132; Fig.19B]. Similarly, at the 30-min time point, an unpaired two-tailed t-test
showed that paclitaxel did not show significant effect on nicotine plasma [t=0.8201; df=7, p=
0.4392; Fig.19C] and cotinine plasma levels [t=1.227; df=7, p= 0.2595; Fig.19D]. These
findings suggested that paclitaxel did not regulate nicotine metabolism.
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Figure 19. Impact of paclitaxel on acute nicotine and cotinine plasma levels.
Mice were pretreated with either paclitaxel (8 mg/kg/day i.p.) or vehicle (1:1:18) and kept 70
days after completion of paclitaxel treatment regimen. Mice were then injected subcutaneously
with nicotine (1 mg/kg/day) at two time points. A) Nicotine and B) cotinine plasma levels 5
min following nicotine treatment. C) Nicotine and D) cotinine plasma levels 30 min following
nicotine treatment. Each point represents the mean ± SEM of n =5 mice per group.
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Paclitaxel significantly attenuated acute nicotine-mediated behaviors
To determine if paclitaxel changes nicotine behavioral sensitivity and in vivo pharmacological
responses, we conducted a series of studies to measure the impact of paclitaxel on behavioral
nicotine responses after acute dosing in mice. C57BL/6J mice were pretreated with paclitaxel
(8mg/kg/day, i.p.) 70 days prior to a single acute injection of nicotine or saline and tested in a
sequence of the following pharmacological responses: antinociception (hot-plate test),
spontaneous activity (locomotor activity boxes) and body temperature (rectal probe).
According to the Ordinary Two-way ANOVA, nicotine produced significant antinociception
indicated by increase in latency in the hot plate test [F (2, 67) = 39.34;

p < 0.0001; Fig.

20A], a significant decrease in locomotor activity [F (2, 73) = 154.5; p < 0.0001; Fig. 20B],
and a decrease in body temperature [F (2, 68) = 47.62; p < 0.0001; Fig. 20C] in vehicle
pretreated mice. Two-way ANOVA followed by a Tukey multiple comparisons test revealed
that paclitaxel pretreatment significantly attenuated a nicotine (1mg/kg/day) induced
hypolocomotion response and hypothermia (p < 0.05). Pretreatment with paclitaxel did not
change the acute nicotine behaviors induced by nicotine dose (2mg/kg/day) (P> 0.05). In
addition, paclitaxel did not induce any changes (P> 0.05) on its own in these assays. These
findings suggest that paclitaxel may regulate some initial pharmacological responses of
nicotine.
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Figure 20. Effect of paclitaxel on acute nicotine-mediated behaviors.
A) Antinociception (hot plate), B) body temperature, and C) locomotor activity was measured
after nicotine or saline administration (s.c.). Paclitaxel (8mg/kg/day i.p.) administered 70 days
prior to nicotine significantly altered acute nicotine behaviors in any test. * Denotes p<0.05
from vehicle-nicotine (1mg/kg/day). Each point represents the mean ± S.E.M. of n= 12-16
mice per group.
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D- Discussion
The present study is the first to report the impact of the chemotherapeutic drug
paclitaxel on the nicotine reward in a mouse CPP paradigm. Our results revealed that paclitaxel
attenuated the development of nicotine CPP in a time-dependent fashion in mice (Fig.16A, B).
In addition, the blockade of nicotine CPP by paclitaxel treatment extended to that morphine
but not to food CPP. While paclitaxel treatment did not affect nicotine’s metabolism, it did
reduce some in vivo nicotinic pharmacological responses after acute dosing.
Our results with nicotine CPP are consistent with previous reports that showed an
inverted U-shaped dose effect curve with a significant preference at the dose of 0.5mg/kg in
mice (Grabus et al., 2006; Sanjakdar et al., 2015; Jackson et al., 2017). We evaluated the effect
of paclitaxel on nicotine CPP at several doses. Paclitaxel completely blocked the development
of nicotine CPP at the dose of 0.5 mg/kg at the late but not the early time point after treatment
with the chemodrug. Because of the nature of the inverted U-shaped dose effect curve observed
in nicotine CPP, it was important to confirm that paclitaxel did not enhance the effects of
nicotine (0.5mg/kg), which would result in a shift to the descending end of the inverted Ushaped dose effect curve for nicotine CPP. We therefore tested the effect of paclitaxel in place
preference induced by a lower dose of nicotine, 0.1 mg/kg (s.c.). We found that paclitaxel did
not enhance the nicotine CPP at lower doses (0.1mg/kg/day) as well as higher doses of nicotine
(1mg/kg/day) (Fig. 16C). Indeed, paclitaxel did not cause left shift (or shift to the ascending
end) of nicotine dose response curve in CPP at lower doses, which suggest a true
pharmacological blockade by paclitaxel.
Similarly, paclitaxel diminished morphine CPP at the late but not the early time point
given at the dose of 10mg/kg (Fig.17A, B). However, palatable food CPP was not reduced by
paclitaxel when we conducted this experiment at late time point (Fig.18).
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The results of the early time point with morphine were consistent with findings of
Neelakantan et al., (2016) and Mori et al., (2014), when they reported that reward-related
behavioral properties and reinforcement of opioids were overall not altered early after
paclitaxel pretreatment. In their studies, they used I.V. self-administration procedure as well as
CPP paradigm to measure the effect of chemotherapy on morphine and fentanyl reward and
reinforcing sensitivity right after the end of treatment. However, we were interested in
exploring the late effects of paclitaxel since we found that it caused long-term changes in
affective behaviors such as anxiety and depression-like behaviors in mice (Toma et al., 2017)
and we also reported time-dependent effect of paclitaxel on various nicotine withdrawal signs
(Chapter 3). Finally, a majority of cancer patients and survivors who quit smoking relapse after
2-3 years of chemotherapy. All of these factors point to the possibility that the chemotherapy
induced long-term brain changes and/or neuronal plasticity that affect the nicotine dependence
in cancer patients and survivors.
One possible mechanism affected by paclitaxel is the mesolimbic dopamine system. In
fact, nicotine rewarding behavior is mediated by high dopaminergic activity in the mesolimbic
system: VTA, nucleous accumbens and PFC (De Biasi et al., 2011; Loughlin et al., 1983;
Lisman et al., 2010). In addition, several studies reported that during nicotine CPP, there was
high dopamine release in nucleus accumbens in rodents (Kashkin and De Witte, 2005; Wise et
al., 1985; Di Chiara et al., 2000). In that regard, paclitaxel could possibly regulate dopamine
signaling in these brain regions by altering the expression of dopaminergic receptors, dopamine
release or dopamine signaling pathways leading to drug reward deficit. Consistent with
aforementioned suggestions, paclitaxel may also alter the Kappa system, which regulates the
dopamine release and involves in dysphoria by enhancing the release of dynorphins ending
with aversive state or reward deficit.
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Paclitaxel may also cause a time-dependent decrease in the acute reward sensitivity by
other mechanisms. The deficit of nicotine sensitivity in the CPP test could be mediated by
pharmacodynamic changes to nicotine’s effects or modulation of nicotine metabolism. First,
nicotine reward deficit at the late time point could cause by reduction in the drug acute
sensitivity. The decrease in nicotine-induced hypomotility and hypothermia seen in our results
suggest this possibility. Changes in nicotinic receptors function, number and regulation by
paclitaxel could explain that reward deficit. For example, acute behavioral tolerance to nicotine
may result from nAChR receptors desensitization (Robinson et al., 2007). In particular,
paclitaxel could desensitize the main nAChR receptors subunits that mediate the nicotine
conditioned reward effect in CPP such as β2 (Walters et al., 2006; Picciotto et al., 1998) and
α6 (Sanjakdar et al., 2006; Pons et al., 2008) subunit-containing nAChRs (α6 and β2-nAChRs).
Secondly, it is also possible that paclitaxel reduced nicotine plasma levels by inducing some
changes in the metabolism of nicotine. Cy2A6 is the main enzyme that is responsible of
nicotine breakdown (Ray et al., 2009). Changing the expression of this protein results in
alterations in nicotine and cotinine blood levels. If paclitaxel acts as an enzyme inducer and
enhances the activity of nicotine metabolizing enzymes, this probably diminishes the nicotine
plasma levels leading to the reduction of nicotine CPP. However, according to our findings
after acute exposure to nicotine, paclitaxel pretreatment did not modify the nicotine and
cotinine plasma levels.
Since conditioned place preference test is a form of Pavlovian conditioning, it was
crucial to know if reduction in nicotine CPP by paclitaxel was not due to memory impairment.
Therefore, we performed high palatable food CPP using chocolate sucrose pellets versus
regular food chow. Interestingly, we found that paclitaxel did not change the food CPP at the
late time point, suggesting that late reduction in nicotine CPP was a real effect and not due to
disruption in the hippocampus-dependent-contextual memory. While long-term use of
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paclitaxel was reported to impair memory in breast cancer patients (Hurria et al., 2006), it is
important to know that there are several types of memories that are mediated by the
hippocampus and here we are interested in cued-dependent memory or contextual memory that
involves in CPP (Nygarda et al., 2015). Collectively, our findings build on the understanding
of the impact of chemotherapy on nicotine reward. Further investigation needs to be conducted
to elucidate the underlying mechanisms.
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CHAPTER FIVE
GENERAL DISCUSSION
A- Discussion
As mentioned in the Introduction of the thesis, around one-third to one-half of smokers
continue smoking after cancer diagnosis despite all the medical and social support to stop
smoking (Garces et al., 2004). The rest of the smoking cancer population showed very high
cessation rates and were very motivated to quit smoking post diagnosis (Cooley et al., 2009;
Davison et al., 1982; Karam- Hage et al., 2016). However, after 2-3 years of chemotherapy,
almost two third of these quitters relapse bringing the relapse rate to 23%, which is similar to
the smoking rates in the general population (Cooley et al., 2009; Davison et al., 1982; KaramHage et al., 2016). They rejoin the general population in terms of smoking rates. This is very
concerning, because tobacco smoking could downtrend the quality of life aspects of cancer
patients, decrease efficacy of chemodrugs and may increase the incidence of secondary tumors
or death (Cox et al., 2002; Vainio et al., 2001; Browman et al., 1993). The causes behind this
smoking pattern and behaviors are numerous. For instance, poor prognosis, tumor site and
type of chemotherapy may play a role in enhancement of smoking behavior among the cancer
population (Davison et al., 1982; Karam- Hage et al., 2016). To the best of our knowledge, no
preclinical research has been conducted to elucidate the underlying factors.
We hypothesized that chemotherapy is a probable factor, since it induces a long-term
aversive negative state in cancer patients and survivors (Massie, 2004; Love et al., 1982;
Reeves et al., 2012; Thornton et al., 2008). Furthermore, chemodrugs elicited neuropathic pain,
and cognitive and emotional deficits such as insomnia, anxiety and anhedonia among cancer
patients and survivors (Massie, 2004; Love et al., 1982; Reeves et al., 2012; Thornton et al.,
2008). Similarly, in animal studies, we observed that the widely used chemotherapeutic agent
paclitaxel caused long-term sensory and emotional deficits (anxiety, anhedonia and depression96

like behaviors) (Toma et al., 2017). Many studies reported that nicotine in tobacco could
enhance memory (Myers et al., 2008), relieve pain (Powledge, 2004; Flood et al., 2004) and
reduce anxiety (Cohen et al., 2000; Kassel et al., 2000). Thus, patients here may smoke to
alleviate the detrimental effects of chemotherapy that appeared early post therapy induction or
later on as long-term side effects. We therefore focused our studies on the impact of
chemotherapy on nicotine dependence in mouse models, to explore the impact of chemodrugs
on two main aspects of nicotine dependence (reward and withdrawal) early and late post
paclitaxel exposure.
We first established a mouse model of nicotine withdrawal that can simultaneously
measure anhedonia- and anxiety-like behaviors and somatic signs (Chapter. 3). In that regard,
we found that during nicotine withdrawal, there was a reduction in sucrose preference, which
suggests a state of anhedonia-like behavior. Also, there was attenuation of the time spent in the
light side in the LDB test, which is indicative of anxiety-like signs during nicotine withdrawal.
Using our newly characterized model (Alkhlaif et al., 2017), we observed that paclitaxel
worsened nicotine withdrawal signs in both the early and the late time points following its
administration. We found significant worsening of anxiety-like behavior and somatic signs of
nicotine withdrawal at the two time points post paclitaxel treatment, but anhedonia-like
behavior was only worsened at the late time point.
Our observation that paclitaxel intensified the nicotine withdrawal signs after
administration of paclitaxel treatment regimen is very significant. Since nicotine withdrawal
plays an important role in smoking relapse, our finding suggests that cancer patients treated
with paclitaxel may experience more intense withdrawal which explain the high relapse rates
in cancer survivors after 2-3 years.
In addition, as we reported in chapter 4, paclitaxel time-dependently attenuated the
reward sensitivity of nicotine in the CPP test through possible pharmacodynamic changes and
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adaptations in nicotinic and non-nicotinic neuronal systems. We suggested that the diminished
capacity for nicotine and morphine reward observed in our mice treated with paclitaxel may
be related to dysfunction of the mesolimbic dopamine (DA) system, a mediator of rewardrelated behavior. Although our initial behavioral findings on nicotine CPP and withdrawal
support this view, much remains unknown about how chemotherapy impacts the DA system
or how such dysregulated DA signaling specifically impacts reward processing. Studies on
chronic pain are informative on this issue. Clinically, dietary DA depletion increases affective
pain ratings (Taylor et al., 2016) and striatal DA release positively correlates with the
magnitude of perceived pain (Brown et al., 2015). Consistent with DA hypofunction, PET
studies have shown that patients suffering from fibromyalgia and chronic back pain exhibit
blunted ventral striatal DA release to acute pain stimuli (Jarcho et al., 2012). It is conceivable
then that the antitumor drug paclitaxel may have induced some alterations in the reward system
through changes in the dopamine signaling. Animal studies suggest similar trends also. It was
shown that arthritic rats self-administered fewer infusions of morphine compared with normal
rats (Lyness et al., 1989), and nerve injury in rats attenuated the rewarding and reinforcing
properties of opioids (Martin et al., 2007; Woller et al., 2012). Furthermore, a recent study
reported that nerve injury, chronic inflammation, and administration of the chemodrug
vincristine diminished acquisition of fentanyl self-administration but not food in mice (Wade
et al., 2013). Consistently, in our findings in chapter 4, we saw that paclitaxel treatment
reduced conditioned morphine reward in CPP sixty days after a drug cycle.
Collectively, paclitaxel and/or its sensory and affective deficits worsened the nicotine
withdrawal and reduced nicotine rewarding sensitivity. An enhanced withdrawal intensity and
a diminished capacity for reward after chemotherapy may be related to dysfunction of the
mesolimbic dopamine system, a mediator of reward-related behavior. Overall, our findings
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suggested that chemotherapy affects nicotine dependence behaviors, but further
neurobiological and behavioral studies are needed to understand these changes.
B- Future directions
The overall future directions of this dissertation are to elucidate the possible
mechanisms mediating the impact of chemotherapy on nicotine dependence. The basis of
nicotine dependence is a combination of positive reinforcements, avoidance of withdrawal
symptoms and conditioning (Govind et al., 2009; Benowitz et al., 2010; Wang and Sun, 2004).
During repeated nicotine exposure, neuroadaptation (tolerance) to some of the effects of
nicotine develops and the number of nACh receptors subsequently upregulated, which
probably occur in response to the nicotine-mediated desensitization. This desensitization plays
a role in nicotine tolerance and dependence, particularly the symptoms of nicotine withdrawal
and relapse. (Govind et al., 2009; Benowitz et al., 2010; Wang and Sun, 2004). Thus, it is
essential to explore the effect of paclitaxel on nicotine reinforcement and reinstatement using
nicotine

intravenous

self-administration

procedure.

Therefore,

measuring

nicotine

reinstatement in mice will more directly address the high relapse rate in cancer survivors after
chemotherapy. We are also planning to address the possible changes in neuronal nicotinic
receptors expression and function after paclitaxel treatment. Finally, our future studies will
address this issue by investigating DAergic mechanisms underlying the affective component
of chemotherapy and by determining whether such effects can be ameliorated through targeted
manipulation of mesolimbic DA signaling.
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